<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=utf-8">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 15">
<meta name=Originator content="Microsoft Word 15">
<link rel=File-List
href="Comprehensive%20Pediatric%20CNS%20Tumor%20Reference%20(WHO%202021%20Classification%20&amp;%20Treatment%20Guide).fld/filelist.xml">
<link rel=Edit-Time-Data
href="Comprehensive%20Pediatric%20CNS%20Tumor%20Reference%20(WHO%202021%20Classification%20&amp;%20Treatment%20Guide).fld/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:CustomDocumentProperties>
  <o:generator dt:dt="string">ChatGPT Deep Research</o:generator>
 </o:CustomDocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData
href="Comprehensive%20Pediatric%20CNS%20Tumor%20Reference%20(WHO%202021%20Classification%20&amp;%20Treatment%20Guide).fld/themedata.thmx">
<link rel=colorSchemeMapping
href="Comprehensive%20Pediatric%20CNS%20Tumor%20Reference%20(WHO%202021%20Classification%20&amp;%20Treatment%20Guide).fld/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:DrawingGridHorizontalSpacing>18 pt</w:DrawingGridHorizontalSpacing>
  <w:DrawingGridVerticalSpacing>18 pt</w:DrawingGridVerticalSpacing>
  <w:DisplayHorizontalDrawingGridEvery>0</w:DisplayHorizontalDrawingGridEvery>
  <w:DisplayVerticalDrawingGridEvery>0</w:DisplayVerticalDrawingGridEvery>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:UseWord2010TableStyleRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
  </w:Compatibility>
  <w:DoNotOptimizeForBrowser/>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" LatentStyleCount="376">
  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" Priority="99" Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="99" SemiHidden="true"
   UnhideWhenUsed="true" Name="Mention"/>
  <w:LsdException Locked="false" Priority="99" SemiHidden="true"
   UnhideWhenUsed="true" Name="Smart Hyperlink"/>
  <w:LsdException Locked="false" Priority="99" SemiHidden="true"
   UnhideWhenUsed="true" Name="Hashtag"/>
  <w:LsdException Locked="false" Priority="99" SemiHidden="true"
   UnhideWhenUsed="true" Name="Unresolved Mention"/>
  <w:LsdException Locked="false" Priority="99" SemiHidden="true"
   UnhideWhenUsed="true" Name="Smart Link"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;
	mso-font-charset:2;
	mso-generic-font-family:auto;
	mso-font-pitch:variable;
	mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
	{font-family:Aptos;
	panose-1:2 11 0 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 3 0 0 415 0;}
@font-face
	{font-family:"Aptos Display";
	panose-1:2 11 0 4 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:536871559 3 0 0 415 0;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:auto;
	mso-font-signature:0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
h1
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 1 Char";
	mso-style-next:"Body Text";
	margin-top:.25in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:20.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:0pt;
	mso-ansi-language:EN;
	font-weight:normal;}
h2
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 2 Char";
	mso-style-next:"Body Text";
	margin-top:8.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:16.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN;
	font-weight:normal;}
h3
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 3 Char";
	mso-style-next:"Body Text";
	margin-top:8.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:14.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN;
	font-weight:normal;}
h4
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 4 Char";
	mso-style-next:"Body Text";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN;
	font-weight:normal;
	font-style:italic;}
h5
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 5 Char";
	mso-style-next:"Body Text";
	margin-top:4.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:5;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN;
	font-weight:normal;}
h6
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 6 Char";
	mso-style-next:"Body Text";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:6;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	mso-ansi-language:EN;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 7 Char";
	mso-style-next:"Body Text";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:7;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	mso-ansi-language:EN;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 8 Char";
	mso-style-next:"Body Text";
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:8;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	mso-ansi-language:EN;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 9 Char";
	mso-style-next:"Body Text";
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:9;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	mso-ansi-language:EN;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-priority:9;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-unhide:no;
	mso-style-link:"Caption Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.MsoFootnoteReference
	{mso-style-unhide:no;
	mso-style-parent:"Caption Char";
	vertical-align:super;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:"Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:Title;
	mso-style-link:"Subtitle Char";
	mso-style-next:"Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:.75pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoSubtitleCxSpFirst, li.MsoSubtitleCxSpFirst, div.MsoSubtitleCxSpFirst
	{mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:Title;
	mso-style-link:"Subtitle Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:.75pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoSubtitleCxSpMiddle, li.MsoSubtitleCxSpMiddle, div.MsoSubtitleCxSpMiddle
	{mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:Title;
	mso-style-link:"Subtitle Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:.75pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoSubtitleCxSpLast, li.MsoSubtitleCxSpLast, div.MsoSubtitleCxSpLast
	{mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:Title;
	mso-style-link:"Subtitle Char";
	mso-style-next:"Body Text";
	mso-style-type:export-only;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	mso-add-space:auto;
	text-align:center;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:.75pt;
	mso-font-kerning:14.0pt;
	mso-ansi-language:EN;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-style-next:"Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	text-align:center;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-parent:"Body Text";
	mso-style-next:"Body Text";
	margin-top:5.0pt;
	margin-right:24.0pt;
	margin-bottom:5.0pt;
	margin-left:24.0pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
a:link, span.MsoHyperlink
	{mso-style-unhide:no;
	mso-style-parent:"Caption Char";
	color:#156082;
	mso-themecolor:accent1;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-unhide:no;
	color:#96607D;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{mso-style-priority:39;
	mso-style-qformat:yes;
	mso-style-parent:"Heading 1";
	mso-style-next:"Body Text";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:20.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-ansi-language:EN;}
p.FirstParagraph, li.FirstParagraph, div.FirstParagraph
	{mso-style-name:"First Paragraph";
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"Body Text";
	mso-style-next:"Body Text";
	margin-top:9.0pt;
	margin-right:0in;
	margin-bottom:9.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.Compact, li.Compact, div.Compact
	{mso-style-name:Compact;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"Body Text";
	margin-top:1.8pt;
	margin-right:0in;
	margin-bottom:1.8pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Title;
	mso-ansi-font-size:28.0pt;
	mso-bidi-font-size:28.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Subtitle;
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	letter-spacing:.75pt;}
p.Author, li.Author, div.Author
	{mso-style-name:Author;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-style-next:"Body Text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	text-align:center;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.AbstractTitle, li.AbstractTitle, div.AbstractTitle
	{mso-style-name:"Abstract Title";
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:Abstract;
	margin-top:15.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:center;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.Abstract, li.Abstract, div.Abstract
	{mso-style-name:Abstract;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-next:"Body Text";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:15.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 1";
	mso-ansi-font-size:20.0pt;
	mso-bidi-font-size:20.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 2";
	mso-ansi-font-size:16.0pt;
	mso-bidi-font-size:16.0pt;
	font-family:"Aptos Display",sans-serif;
	mso-ascii-font-family:"Aptos Display";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Aptos Display";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 3";
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;
	font-style:italic;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#0F4761;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 8";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 9";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;}
p.FootnoteBlockText, li.FootnoteBlockText, div.FootnoteBlockText
	{mso-style-name:"Footnote Block Text";
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-parent:"Footnote Text";
	mso-style-next:"Footnote Text";
	margin-top:5.0pt;
	margin-right:24.0pt;
	margin-bottom:5.0pt;
	margin-left:24.0pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.DefinitionTerm, li.DefinitionTerm, div.DefinitionTerm
	{mso-style-name:"Definition Term";
	mso-style-unhide:no;
	mso-style-next:Definition;
	margin:0in;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.Definition, li.Definition, div.Definition
	{mso-style-name:Definition;
	mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.TableCaption, li.TableCaption, div.TableCaption
	{mso-style-name:"Table Caption";
	mso-style-unhide:no;
	mso-style-parent:Caption;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.ImageCaption, li.ImageCaption, div.ImageCaption
	{mso-style-name:"Image Caption";
	mso-style-unhide:no;
	mso-style-parent:Caption;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;
	font-style:italic;
	mso-bidi-font-style:normal;}
p.Figure, li.Figure, div.Figure
	{mso-style-name:Figure;
	mso-style-unhide:no;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
p.CaptionedFigure, li.CaptionedFigure, div.CaptionedFigure
	{mso-style-name:"Captioned Figure";
	mso-style-unhide:no;
	mso-style-parent:Figure;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
span.CaptionChar
	{mso-style-name:"Caption Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Caption;}
span.VerbatimChar
	{mso-style-name:"Verbatim Char";
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-parent:"Caption Char";
	mso-style-link:"Source Code";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;}
span.SectionNumber
	{mso-style-name:"Section Number";
	mso-style-unhide:no;
	mso-style-parent:"Caption Char";}
p.SourceCode, li.SourceCode, div.SourceCode
	{mso-style-name:"Source Code";
	mso-style-unhide:no;
	mso-style-link:"Verbatim Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	mso-pagination:widow-orphan;
	word-break:break-all;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-ansi-language:EN;}
span.KeywordTok
	{mso-style-name:KeywordTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#007020;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.DataTypeTok
	{mso-style-name:DataTypeTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#902000;}
span.DecValTok
	{mso-style-name:DecValTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#40A070;}
span.BaseNTok
	{mso-style-name:BaseNTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#40A070;}
span.FloatTok
	{mso-style-name:FloatTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#40A070;}
span.ConstantTok
	{mso-style-name:ConstantTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#880000;}
span.CharTok
	{mso-style-name:CharTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#4070A0;}
span.SpecialCharTok
	{mso-style-name:SpecialCharTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#4070A0;}
span.StringTok
	{mso-style-name:StringTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#4070A0;}
span.VerbatimStringTok
	{mso-style-name:VerbatimStringTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#4070A0;}
span.SpecialStringTok
	{mso-style-name:SpecialStringTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#BB6688;}
span.ImportTok
	{mso-style-name:ImportTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:green;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.CommentTok
	{mso-style-name:CommentTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#60A0B0;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.DocumentationTok
	{mso-style-name:DocumentationTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#BA2121;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.AnnotationTok
	{mso-style-name:AnnotationTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#60A0B0;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.CommentVarTok
	{mso-style-name:CommentVarTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#60A0B0;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.OtherTok
	{mso-style-name:OtherTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#007020;}
span.FunctionTok
	{mso-style-name:FunctionTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#06287E;}
span.VariableTok
	{mso-style-name:VariableTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#19177C;}
span.ControlFlowTok
	{mso-style-name:ControlFlowTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#007020;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.OperatorTok
	{mso-style-name:OperatorTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#666666;}
span.BuiltInTok
	{mso-style-name:BuiltInTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:green;}
span.ExtensionTok
	{mso-style-name:ExtensionTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;}
span.PreprocessorTok
	{mso-style-name:PreprocessorTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#BC7A00;}
span.AttributeTok
	{mso-style-name:AttributeTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#7D9029;}
span.RegionMarkerTok
	{mso-style-name:RegionMarkerTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;}
span.InformationTok
	{mso-style-name:InformationTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#60A0B0;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.WarningTok
	{mso-style-name:WarningTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:#60A0B0;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;}
span.AlertTok
	{mso-style-name:AlertTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:red;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.ErrorTok
	{mso-style-name:ErrorTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;
	color:red;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
span.NormalTok
	{mso-style-name:NormalTok;
	mso-style-unhide:no;
	mso-style-parent:"Verbatim Char";
	mso-ansi-font-size:11.0pt;
	font-family:"Consolas",serif;
	mso-ascii-font-family:Consolas;
	mso-hansi-font-family:Consolas;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Aptos;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:0pt;
	mso-ligatures:none;
	mso-ansi-language:EN;}
.MsoPapDefault
	{mso-style-type:export-only;
	margin-bottom:10.0pt;}
 /* Page Definitions */
 @page
	{mso-footnote-numbering-restart:each-section;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;
	mso-footnote-numbering-restart:each-section;}
 /* List Definitions */
 @list l0
	{mso-list-id:43408;
	mso-list-template-ids:-1132934272;}
@list l0:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level2
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level3
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level4
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level5
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level6
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level7
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level8
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l0:level9
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:" ";
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;}
@list l1
	{mso-list-id:43409;
	mso-list-template-ids:-1344907602;}
@list l1:level1
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;
	mso-bidi-font-family:Symbol;}
@list l1:level2
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level3
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;
	mso-bidi-font-family:Wingdings;}
@list l1:level4
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;
	mso-bidi-font-family:Symbol;}
@list l1:level5
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level6
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;
	mso-bidi-font-family:Wingdings;}
@list l1:level7
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Symbol;
	mso-bidi-font-family:Symbol;}
@list l1:level8
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:o;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:"Courier New";}
@list l1:level9
	{mso-level-start-at:0;
	mso-level-number-format:bullet;
	mso-level-text:;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	text-indent:-.25in;
	font-family:Wingdings;
	mso-bidi-font-family:Wingdings;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin-top:0in;
	mso-para-margin-right:0in;
	mso-para-margin-bottom:10.0pt;
	mso-para-margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-ansi-language:EN;}
table.Table
	{mso-style-name:Table;
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin-top:0in;
	mso-para-margin-right:0in;
	mso-para-margin-bottom:10.0pt;
	mso-para-margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;
	mso-ascii-font-family:Aptos;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Aptos;
	mso-hansi-theme-font:minor-latin;
	mso-ansi-language:EN;}
table.TableFirstRow
	{mso-style-name:Table;
	mso-table-condition:first-row;
	mso-style-noshow:yes;
	mso-style-qformat:yes;
	mso-style-parent:"";
	mso-tstyle-vert-align:bottom;
	mso-tstyle-border-bottom:.25pt solid windowtext;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US link="#156082" vlink="#96607D" style='tab-interval:.5in;
word-wrap:break-word'>

<div class=WordSection1>

<h1><a name=Xb575b9c3c2a588539640afd7a5ef21f8a9601f7></a><a name=content></a><a
name=header></a><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span lang=EN>Comprehensive Pediatric CNS Tumor
Reference (WHO 2021 Classification &amp; Treatment Guide)</span></span></span></h1>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=table-of-contents><span lang=EN>Table of
Contents</span></a></span></span></h2>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Pediatric Low-Grade Gliomas
(Diffuse &amp; Circumscribed)</span></b></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#pediatric-type-diffuse-low-grade-gliomas"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Pediatric-type Diffuse
Low-Grade Gliomas</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Diffuse Astrocytoma, MYB-
or MYBL1-altered</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#angiocentric-glioma"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Angiocentric Glioma</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#Xdcef570b3e598523c94a06e2924918e875ace4a"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Polymorphous Low-Grade
Neuroepithelial Tumor of the Young</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo3'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X37fcad5f99159400a261fcd68d2ead95e4a4dfe"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Diffuse Low-Grade Glioma,
MAPK Pathwayaltered</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X3d57c7607d8c3e7b43203972389eb9a6d5aaced"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Circumscribed Low-Grade
Astrocytic Tumors</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo4'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#pilocytic-astrocytoma-grade-1"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Pilocytic Astrocytoma (Grade 1)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo4'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#subependymal-giant-cell-astrocytoma-sega"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Subependymal Giant Cell
Astrocytoma (SEGA)</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo4'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#pleomorphic-xanthoastrocytoma-pxa"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Pleomorphic Xanthoastrocytoma (PXA)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span><a
     href="#neuronal-and-mixed-neuronal-glial-tumors"><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><span lang=EN>Neuronal and Mixed
     Neuronal-Glial Tumors</span></span></span></span><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span></a><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></li>
</ul>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo5'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a href="#ganglioglioma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Ganglioglioma</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo5'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X902756117527ef83fcf6a6dee44116745d48044"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Dysembryoplastic
Neuroepithelial Tumor (DNET)</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo5'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X0c19a0f6c4e21fc3e40b2ad7a2a4a2b0644f90f"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Diffuse Glioneuronal Tumor
with Oligodendroglioma-like Features (DGONC)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo5'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#other-rare-low-grade-neuronal-tumors"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Other Rare Low-Grade Neuronal Tumors</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><b><span lang=EN>Pediatric
     High-Grade Gliomas</span></b></span></span></span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span><a
     href="#X6e50780403ca1edb68ccef105477012f967f269"><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><span lang=EN>Pediatric-type
     Diffuse High-Grade Gliomas</span></span></span></span><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></li>
</ul>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo6'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#Xba332aac03655841400cb310ce2c7248849ace3"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Diffuse Midline Glioma, H3
K27-altered (DIPG)</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo6'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#diffuse-hemispheric-glioma-h3-g34-mutant"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Diffuse Hemispheric
Glioma, H3 G34-mutant</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo6'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X497ff99086d7d9c1f18b25f44abf3a1cf9fae91"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Diffuse Pediatric
High-Grade Glioma, H3/IDH-wildtype</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo6'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#infant-type-hemispheric-glioma"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Infant-Type Hemispheric Glioma</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo6'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>High-Grade Astrocytoma
with Piloid Features</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><b><span lang=EN>Ependymal Tumors</span></b></span></span></span></li>
</ul>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X8fd4954ca5d44c3a0e2f9a987e972aef316301d"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Supratentorial Ependymoma
(ZFTA fusion-positive &amp; YAP1 fusion-positive)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X1bf15c91cc5eefe7c6fc19669d23cda93ccfc2c"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Posterior Fossa Ependymoma
(Group PFA &amp; PFB)</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#Xb26e079c797e746e4f745f273aedfb86a75461e"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Spinal Ependymoma (incl.
MYCN-amplified subtype)</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#myxopapillary-ependymoma"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Myxopapillary Ependymoma</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span><a
     href="#subependymoma"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
     lang=EN>Subependymoma</span></span></span></span><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span></a><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><b><span lang=EN>Choroid Plexus
     Tumors</span></b></span></span></span></li>
</ul>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#choroid-plexus-papilloma"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Choroid Plexus Papilloma</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span><a
     href="#choroid-plexus-carcinoma"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
     lang=EN>Choroid Plexus Carcinoma</span></span></span></span><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><b><span lang=EN>Embryonal Tumors</span></b></span></span></span></li>
</ul>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a href="#medulloblastoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Medulloblastoma</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#atypical-teratoidrhabdoid-tumor-atrt"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Atypical Teratoid/Rhabdoid Tumor (ATRT)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X76e2627d5aa903eb49c0db0208e307ddb4e3ca8"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Embryonal Tumor with
Multilayered Rosettes (ETMR)</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#cns-neuroblastoma-foxr2-activated"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>CNS Neuroblastoma, FOXR2-activated</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X57f64594ef069ce1e6d6f57529d6c5d8229acdd"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>CNS Tumor with BCOR
Internal Tandem Duplication</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span><a
     href="#other-rare-embryonal-tumors"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
     lang=EN>Other Rare Embryonal Tumors</span></span></span></span><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><b><span lang=EN>Germ Cell Tumors
     (GCTs)</span></b></span></span></span></li>
</ul>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a href="#germinoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Germinoma</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span><a
     href="#non-germinomatous-gcts-nggct"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
     lang=EN>Non-Germinomatous GCTs (NGGCT)</span></span></span></span><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></li>
</ul>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo7'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a href="#teratoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Teratoma</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo7'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#yolk-sac-tumor-endodermal-sinus-tumor"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Yolk Sac Tumor (Endodermal Sinus Tumor)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo7'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a href="#choriocarcinoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Choriocarcinoma</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo7'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#embryonal-carcinoma"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Embryonal Carcinoma</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo7'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#mixed-germ-cell-tumors"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Mixed Germ Cell Tumors</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><b><span lang=EN>Sellar Region
     Tumors</span></b></span></span></span></li>
</ul>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a href="#craniopharyngioma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Craniopharyngioma</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span><a
     href="#Xb993388c579b7a3eeea6f0d1538c47524545021"><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><span lang=EN>Pituitary Adenomas
     and Pituitary Blastoma</span></span></span></span><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span></a><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><b><span lang=EN>Pineal Region
     Tumors</span></b></span></span></span></li>
</ul>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a href="#pineoblastoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Pineoblastoma</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X4c973d1473fe60277adf7bd9ca2034783bc1a36"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Pineal Parenchymal Tumors
(PPTID &amp; Pineocytoma)</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#papillary-tumor-of-the-pineal-region"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Papillary Tumor of the Pineal Region</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span><a
     href="#X62e75e83306ba11770820288fd1cf434176ef9a"><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><span lang=EN>Desmoplastic Myxoid
     Tumor of Pineal Region, SMARCB1-mutant</span></span></span></span><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><b><span lang=EN>Meningeal and
     Mesenchymal Tumors</span></b></span></span></span></li>
</ul>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#pediatric-meningiomas"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Pediatric Meningiomas</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span><a
     href="#X933949c4ed009e610a5766637746532d6150893"><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><span lang=EN>Mesenchymal CNS
     Tumors (Intracranial Sarcomas)</span></span></span></span><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></li>
</ul>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo8'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a href="#chordoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Chordoma</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo8'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#Xb1552a0fae6647e2e5791478b2c0e892725a173"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Intracranial Mesenchymal
Tumor, FET-CREB Fusion-positive</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo8'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#cic-rearranged-sarcoma"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>CIC-rearranged Sarcoma</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo8'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X6ab5bd7d63b76e3e685a11e1dd64ddf12461fb4"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Primary Intracranial
Sarcoma, DICER1-mutant</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:1.0in;text-indent:-.25in;mso-list:l1 level2 lfo8'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a href="#hemangioblastoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Hemangioblastoma</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><b><span lang=EN>Nerve Sheath
     Tumors</span></b></span></span></span></li>
</ul>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#schwannomas-vestibular-schwannoma"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Schwannomas (Vestibular Schwannoma)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'></span></span></span><a
     href="#other-nerve-sheath-tumors"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
     lang=EN>Other Nerve Sheath Tumors</span></span></span></span><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
     style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
     style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo2'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:table-of-contents'><b><span lang=EN>Tumor
     Predisposition Syndromes</span></b><span lang=EN> (relevant to pediatric
     CNS tumors)</span></span></span></span></li>
</ul>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#neurofibromatosis-type-1-nf1"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Neurofibromatosis Type 1 (NF1)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#neurofibromatosis-type-2-nf2"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Neurofibromatosis Type 2 (NF2)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#tuberous-sclerosis-complex-tsc"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Tuberous Sclerosis Complex (TSC)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#li-fraumeni-syndrome-lfs"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Li-Fraumeni Syndrome (LFS)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#Xd5479182ada802bea2f9018982bc9b3754420df"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Gorlin Syndrome (Nevoid
Basal Cell Carcinoma Syndrome)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#turcot-syndrome-fap-and-lynch-subtypes"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Turcot Syndrome (FAP and Lynch subtypes)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X777dc7e045bea7d2422726c7cdef6d5ff877be3"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Rhabdoid Tumor
Predisposition (SMARCB1/SMARCA4 mutations)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a href="#dicer1-syndrome"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>DICER1 Syndrome</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#cowden-syndrome-pten-hamartoma-syndrome"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Cowden Syndrome (PTEN hamartoma syndrome)</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#von-hippellindau-vhl-disease"><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN>Von HippelLindau (VHL) Disease</span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]></span></span></span><a
href="#X8190de060ffe98da450190550a941f1cb41bb78"><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'><span lang=EN>Constitutional Mismatch
Repair Deficiency (CMMRD)</span></span></span></span><span style='mso-bookmark:
Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
style='mso-bookmark:table-of-contents'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'></span></span></span></p>

<div class=MsoNormal align=center style='text-align:center'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:table-of-contents'><span
lang=EN style='mso-no-proof:yes'>

<hr size=0 width="100%" align=center>

</span></span></span></span></div>

<span style='mso-bookmark:table-of-contents'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=X0af533689dcb0b9ec304f3da0c1376144cc4488><span
lang=EN>Pediatric Low-Grade Gliomas (Diffuse &amp; Circumscribed)</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>Pediatric low-grade gliomas (pLGGs) are the most common childhood CNS
tumors</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20Low%20Grade%20Glioma%20Introduction%3A,14%2C%2015%29%2C%20otherwise"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>[1]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>. They encompass WHO grade I and II gliomas</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20Low%20Grade%20Glioma%20Introduction%3A,14%2C%2015%29%2C%20otherwise"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>[1]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>. Unlike adult LGGs (often defined by IDH mutation and 1p/19q
codeletion), pediatric LGGs are usually driven by aberrations in the MAPK
pathway (e.g. <i>BRAF</i> alterations) and rarely involve IDH mutations</span></span></span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=also%20revealed%20important%20dif%EF%BF%BEferences%20between,While%20targeted%20therapy%20trials"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>[2]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>. In fact, the majority of pLGGs have alterations like <i>KIAA1549-BRAF</i>
fusions, <i>BRAF^V600E</i> mutations, or FGFR1/MYB alterations, distinct from
adult patterns</span></span></span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=also%20revealed%20important%20dif%EF%BF%BEferences%20between,While%20targeted%20therapy%20trials"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>[2]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>. This has opened the door to targeted therapies (e.g. BRAF and MEK
inhibitors) which are being evaluated and may supplant traditional chemotherapy
for pLGGs</span></span></span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=gliomas%20,challenge%20in%20a%20group%20of"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>[3]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
lang=EN>.</span></span></span></span></p>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><a
name=pediatric-type-diffuse-low-grade-gliomas><span lang=EN>Pediatric-type
Diffuse Low-Grade Gliomas</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>WHO
2021 introduced a new category pediatric-type diffuse low-grade gliomas,
distinct from adult diffuse gliomas</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Pediatric,neuroepithelial%20tumor%20of%20the%20young"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[4]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>.
These tumors are generally diffuse (infiltrative) WHO grade 2 gliomas that
occur in children and lack IDH mutations. The main subtypes include: <b>Diffuse
astrocytoma, MYB- or MYBL1-altered; Angiocentric glioma; Polymorphous low-grade
neuroepithelial tumor of the young;</b> and <b>Diffuse low-grade glioma, MAPK
pathwayaltered</b></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Newly%20Recognized%20Tumor%20Types%20Diffuse,provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[5]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Diffuse%20astrocytoma%2C%20MYB,provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[6]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>.
All have relatively favorable prognoses compared to high-grade gliomas</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Pediatric,to%20their%20more%20solid%20growth"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[7]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>.
Key features and diagnostic criteria are:</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo9'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical/Radiologic:</span></b><span
lang=EN> These present often with seizures or focal deficits depending on
location (commonly cerebral hemispheres or thalamus). MRI typically shows
T2/FLAIR hyperintense, non-enhancing or mildly enhancing infiltrative lesions.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo9'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histopathology:</span></b><span
lang=EN> Generally show low-grade astrocytic or mixed astro-glial morphology
without anaplasia. Angiocentric glioma is characterized by an angiocentric
pattern of monomorphic bipolar cells.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo9'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo9'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><i><span lang=EN>Diffuse astrocytoma, MYB- or
MYBL1-altered</span></i><span lang=EN>  defined by gene fusions or
amplification involving <b>MYB</b> or <b>MYBL1</b></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Newly%20Recognized%20Tumor%20Types%20Diffuse,provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[5]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo9'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><i><span lang=EN>Angiocentric glioma</span></i><span
lang=EN>  often has <b>MYB-QKI</b> fusion as a molecular hallmark.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo9'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><i><span lang=EN>Polymorphous low-grade
neuroepithelial tumor of the young (PLNTY)</span></i><span lang=EN>  recently
characterized, often carries <b>BRAF^V600E</b> mutations and shows
oligodendroglioma-like appearance with neuronal markers.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo9'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><i><span lang=EN>Diffuse low-grade glioma, MAPK
pathwayaltered</span></i><span lang=EN>  a broad category for diffuse gliomas
driven by MAPK alterations (e.g. fusions in BRAF, FGFR1-TACC, etc.)</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Newly%20Recognized%20Tumor%20Types%20Diffuse,provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[5]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo9'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Immunohistochemistry (IHC):</span></b><span
lang=EN> Variable glial markers (GFAP often positive). PLNTY often has strong
CD34 immunopositivity in tumor cells and in ramified neural elements, a feature
it shares with dysembryoplastic neuroepithelial tumor.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo9'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>WHO Grade:</span></b><span
lang=EN> Assigned WHO grade 1 or 2 depending on features, but generally
considered low-grade.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo9'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> If feasible, surgical resection (especially for accessible lesions) is
first-line and can be curative for small circumscribed tumors. For unresectable
or progressive diffuse LGGs, standard first-line therapy has been chemotherapy.
<b>Chemotherapy:</b> A common regimen is weekly vincristine plus carboplatin
for ~18 months (the Packer regimen), or in some centers, weekly vinblastine
monotherapy for 70 weeks</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Vinblastine%205%20mg%2Fm2,vinblastine%20monotherapy%20protocol%20for%20details"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[8]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>.
In Canadian practice, single-agent vinblastine is often used as first-line for
pLGG</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Low%20Grade%20Glioma%201st%20Line,with%20additional%20IT%20chemotherapy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[9]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>. <b>Targeted
therapy:</b> If a targetable mutation is present (e.g. <i>BRAF^V600E</i> or
NF1-related pathway), a targeted inhibitor (such as a MEK inhibitor or BRAF
inhibitor) is recommended at recurrence or as second-line</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Low%20Grade%20Glioma%201st%20Line,with%20additional%20IT%20chemotherapy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[9]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>.
In fact, consensus is to use a MAPK pathway inhibitor (like selumetinib or
dabrafenib/trametinib) in second line if a MAPK alteration is identified</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Low%20Grade%20Glioma%201st%20Line,per%20ACNS0331%20with%20boost%20to"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[10]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>. <b>Radiation:</b>
Generally avoided or delayed in young children due to long-term toxicity;
reserved for refractory cases or older teens. Overall survival of pLGG is
excellent (~8590% at 10 years) but progression-free survival is lower (~42% at
10 years) due to frequent indolent recurrences</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20Low%20Grade%20Glioma%20Introduction%3A,14%2C%2015%29%2C%20otherwise"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>[11]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span lang=EN>.</span></span></span></span></span></p>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><a
name=X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2><span lang=EN>Diffuse
Astrocytoma, MYB- or MYBL1-altered</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2'><span lang=EN>This
subtype is a diffuse astrocytoma typically occurring in children and defined by
alterations in MYB or MYBL1 genes (often gene fusions or amplifications)</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Newly%20Recognized%20Tumor%20Types%20Diffuse,provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2'><span lang=EN>[5]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2'><span lang=EN>.
It was newly recognized in WHO 2021.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo10'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Diagnostic:</span></b><span
lang=EN> Histologically resembles a diffuse astrocytoma (WHO grade 2) with
relatively bland, fibrillary astrocytic cells. Key to diagnosis is identifying
a MYB or MYBL1 fusion (e.g. MYB-QKI) or amplification. These tumors often occur
in cerebral hemispheres of older children or adolescents.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo10'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC/Molecular:</span></b><span
lang=EN> Often OLIG2 and GFAP positive (astrocytic). The MYB-QKI fusion can be
detected by FISH or sequencing; it leads to upregulation of MYB oncogene.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo10'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical:</span></b><span
lang=EN> Patients may present with seizures or headaches depending on tumor
location.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo10'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Maximal safe resection if feasible. If residual tumor or progression,
treat as pLGG (chemotherapy such as carboplatin/vincristine or vinblastine).
Prognosis is generally favorable (low-grade behavior).</span></span></span></span></span></span></p>

<span style='mso-bookmark:X9d86ea15c8c839a4d3563ae4f5a95a2f0feead2'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><a
name=angiocentric-glioma><span lang=EN>Angiocentric Glioma</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:angiocentric-glioma'><span lang=EN>Angiocentric glioma is a
rare epilepsy-associated tumor of children/young adults, often centered in the
cortical or thalamic region. It is characterized by an angiocentric
(vessel-centered) growth pattern of bipolar tumor cells.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo11'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:angiocentric-glioma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Diagnostic:</span></b><span
lang=EN> Shows monomorphic bipolar spindle cells arrayed around blood vessels
(forming pseudo-rosettes). It is WHO grade 1 or 2. Often causes drug-resistant
seizures.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo11'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:angiocentric-glioma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> A hallmark is the <b>MYB-QKI</b> fusion in a significant subset</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Newly%20Recognized%20Tumor%20Types%20Diffuse,provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:angiocentric-glioma'><span lang=EN>[5]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:angiocentric-glioma'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:angiocentric-glioma'><span lang=EN>.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo11'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:angiocentric-glioma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN>
Usually GFAP positive and EMA dot staining may be seen (suggesting ependymal
differentiation).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo11'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:angiocentric-glioma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Surgical resection can be curative and often stops seizures. Excellent
prognosis when fully resected. Unresectable cases could be observed or treated
with chemotherapy if needed, but surgery is primary.</span></span></span></span></span></span></p>

<span style='mso-bookmark:angiocentric-glioma'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><a
name=Xe28ff22e9218a45268fe9f6093f07a880e9096c><span lang=EN>Polymorphous
Low-Grade Neuroepithelial Tumor of the Young (PLNTY)</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:Xe28ff22e9218a45268fe9f6093f07a880e9096c'><span lang=EN>PLNTY
is a newly defined tumor (WHO 2021) typically affecting children and
adolescents with chronic seizures. It often appears as a cortical/subcortical
lesion.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo12'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:Xe28ff22e9218a45268fe9f6093f07a880e9096c'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Diagnostic:</span></b><span
lang=EN> Histology shows a polymorphous population of cells with both neuronal
and glial features and calcifications. It resembles oligodendroglioma in some
ways but occurs in young patients without 1p/19q co-deletion.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo12'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:Xe28ff22e9218a45268fe9f6093f07a880e9096c'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Frequently carries <i>BRAF^V600E</i> mutations</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Newly%20Recognized%20Tumor%20Types%20Diffuse,provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:Xe28ff22e9218a45268fe9f6093f07a880e9096c'><span lang=EN>[5]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:Xe28ff22e9218a45268fe9f6093f07a880e9096c'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:Xe28ff22e9218a45268fe9f6093f07a880e9096c'><span lang=EN>.
Lacks IDH mutation.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo12'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:Xe28ff22e9218a45268fe9f6093f07a880e9096c'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN>
Strong diffuse CD34 positivity is characteristic, and neuronal markers
(synaptophysin) can be focally positive, reflecting mixed neuroepithelial
nature.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo12'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:Xe28ff22e9218a45268fe9f6093f07a880e9096c'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Surgical resection is often curative; these tumors are indolent.
Seizure outcomes are good after surgery. If residual tumor causes issues, could
consider targeted BRAF inhibitor in <i>BRAF^V600E</i> cases or standard chemo,
but usually not necessary.</span></span></span></span></span></span></p>

<span style='mso-bookmark:Xe28ff22e9218a45268fe9f6093f07a880e9096c'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><a
name=X37fcad5f99159400a261fcd68d2ead95e4a4dfe><span lang=EN>Diffuse Low-Grade
Glioma, MAPK Pathwayaltered</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'><span lang=EN>This
is an inclusive category for pediatric diffuse gliomas driven by MAPK pathway
alterations (aside from the specific MYB, etc. above)</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Newly%20Recognized%20Tumor%20Types%20Diffuse,provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'><span lang=EN>[5]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'><span lang=EN>.
It encompasses tumors that might have historically been diffuse astrocytoma
NOS in a child but now recognized to have e.g. BRAF fusion or other kinase
fusions.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo13'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Diagnostic:</span></b><span
lang=EN> Diffuse, infiltrative low-grade glial tumor in a child, lacking
defining features of other categories but with a known MAPK genetic driver.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo13'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Alterations can include <i>KIAA1549-BRAF</i> fusion (common in
pilocytic but can occur in diffuse), FGFR1 mutations or fusions, NTRK fusions,
etc. Essentially, any MAPK pathway activation qualifies (excluding MYB family
which is separate category).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo13'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Similar to other pLGGs  surgery if possible; otherwise observe or
treat with chemotherapy. Importantly, if a targetable mutation (e.g. BRAF
fusion) is present, targeted therapy (like a MEK inhibitor) is an option and
increasingly used as second-line</span></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Low%20Grade%20Glioma%201st%20Line,per%20ACNS0331%20with%20boost%20to"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'><span lang=EN>[10]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'><span lang=EN>.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo13'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'><span
style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Generally very good long-term survival.</span></span></span></span></span></span></p>

<span style='mso-bookmark:X37fcad5f99159400a261fcd68d2ead95e4a4dfe'></span><span
style='mso-bookmark:pediatric-type-diffuse-low-grade-gliomas'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><a
name=X3d57c7607d8c3e7b43203972389eb9a6d5aaced><span lang=EN>Circumscribed
Low-Grade Astrocytic Tumors</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span lang=EN>These
are WHO grade 1 tumors that are typically well-circumscribed (non-diffuse) and
often amenable to surgical cure. They fall under circumscribed astrocytic
gliomas in WHO classification. Key pediatric examples: <b>Pilocytic
astrocytoma, Subependymal giant cell astrocytoma,</b> and <b>Pleomorphic
xanthoastrocytoma</b>. These tumors tend to have specific molecular profiles
(e.g. pilocytic has KIAA1549-BRAF fusion in ~70% cases).</span></span></span></span></span></p>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><a
name=pilocytic-astrocytoma-grade-1><span lang=EN>Pilocytic Astrocytoma (Grade
1)</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><span lang=EN>Pilocytic
astrocytoma (PA) is the quintessential benign pediatric brain tumor (WHO grade
1). It most commonly arises in the cerebellum, but also optic pathway
(especially in NF1 patients) and brainstem.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo14'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical/Radiologic:</span></b><span
lang=EN> Often presents with symptoms of a mass in respective location (e.g.
cerebellar PA causes headache, ataxia; optic pathway glioma causes vision
loss). MRI typically shows a cystic mass with an enhancing mural nodule in the
cerebellum, or a solid hypothalamic/optic chiasm mass.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo14'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histopathology:</span></b><span
lang=EN> Biphasic pattern  areas of compact bipolar cells with Rosenthal
fibers and areas of loose microcystic change. Generally low cellularity and no
atypical mitoses.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo14'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Approximately 70% have <b>KIAA1549-BRAF</b> fusion activating the MAPK
pathway</span></span></span></span></span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=also%20revealed%20important%20dif%EF%BF%BEferences%20between,While%20targeted%20therapy%20trials"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><span lang=EN>[2]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><span lang=EN>.
NF1-associated PAs have NF1 gene loss as the driver. Rarely BRAF^V600E in
non-cerebellar PAs.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo14'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN>
GFAP positive (astrocytic), and often a characteristic pattern of p16 (CDKN2A)
is intact (in contrast to high-grades).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo14'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> <b>Surgery</b> is often curative if complete resection is possible
(especially for cerebellar PAs)  5-year survival ~95%. For tumors in critical
locations (optic pathway, brainstem) or subtotally resected tumors, observation
is an option if stable. If progression occurs, <b>chemotherapy</b> is
first-line (particularly in young children to avoid radiation). Standard
regimens include carboplatin/vincristine for 1218 months</span></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Low%20Grade%20Glioma%201st%20Line,with%20additional%20IT%20chemotherapy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><span lang=EN>[9]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><span lang=EN>.
Alternatively weekly vinblastine is used in some centers</span></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Low%20Grade%20Glioma%201st%20Line,per%20ACNS0331%20with%20boost%20to"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><span lang=EN>[10]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><span lang=EN>. <b>Targeted
therapy:</b> Selumetinib (a MEK inhibitor) has shown efficacy in NF1 optic
pathway gliomas and other PAs</span></span></span></span></span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=gliomas%20,challenge%20in%20a%20group%20of"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><span lang=EN>[3]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><span lang=EN>; it may
become standard for progressive cases with MAPK alterations. <b>Radiation:</b>
Typically avoided in young children; could be considered in older patients or
if tumor threatens vision/life and is refractory to chemo, but carries risk of
long-term cognitive and vasculopathic effects.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo14'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pilocytic-astrocytoma-grade-1'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Excellent overall survival. Recurrences can often be managed with
further therapy. Transformation to higher grade is very rare.</span></span></span></span></span></span></p>

<span style='mso-bookmark:pilocytic-astrocytoma-grade-1'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><a
name=subependymal-giant-cell-astrocytoma-sega><span lang=EN>Subependymal Giant
Cell Astrocytoma (SEGA)</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'><span lang=EN>SEGA
is a benign tumor (WHO grade 1) almost exclusively seen in the setting of <b>Tuberous
Sclerosis Complex (TSC)</b>. It typically arises in the lateral ventricle near
the foramen of Monro, often causing hydrocephalus.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo15'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical:</span></b><span
lang=EN> Usually presents in children or adolescents with TSC, often when tumor
enlargement causes obstructive hydrocephalus (headache, increased intracranial
pressure). TSC stigmata like seizures, skin lesions, etc., are present.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo15'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> As the name suggests, contains large epithelioid giant astrocytes
with abundant cytoplasm and often multinucleation. They can calcify. Despite
alarming histology, behavior is benign.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo15'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Caused by loss of <b>TSC1 or TSC2</b> genes (TSC patients carry
germline mutation, and SEGA is a result of biallelic inactivation). This leads
to mTOR pathway activation.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo15'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN> Positive
for GFAP and often S100; can also express neuronal markers like synaptophysin
(reflecting mixed glioneuronal features).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo15'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Traditionally, surgical resection was standard if the SEGA was causing
hydrocephalus. However, <b>mTOR inhibitors</b> (like everolimus) have become a
cornerstone therapy, often leading to significant tumor shrinkage in TSC
patients</span></span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=TSC1%2C%20TSC2%20Subependymal%20giant%20cell,astrocytoma%20Renal%20angiomyolipoma%2C%20cardiac%20rhabdomyoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'><span lang=EN>[12]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'><span lang=EN>.
Everolimus is often the first-line treatment now, potentially obviating need
for surgery in many cases.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo15'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Excellent; tumors generally stop growing in adulthood. Management is
aimed at preventing hydrocephalus and treating before vision/cognitive issues
occur.</span></span></span></span></span></span></p>

<span style='mso-bookmark:subependymal-giant-cell-astrocytoma-sega'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><a
name=pleomorphic-xanthoastrocytoma-pxa><span lang=EN>Pleomorphic
Xanthoastrocytoma (PXA)</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pleomorphic-xanthoastrocytoma-pxa'><span lang=EN>PXA is an
unusual astrocytoma (typically WHO grade 2) often occurring in children and
young adults, usually superficially in the cerebral hemispheres (temporal lobe
is common). Many patients have seizures.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo16'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pleomorphic-xanthoastrocytoma-pxa'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> As the name pleomorphic xanthoastrocytoma suggests, it has
pleomorphic, lipid-laden astrocytes (xanthomatous cells) and often dense
lymphocytic infiltrates. Despite cytologic atypia, mitotic activity is low in
grade 2 PXA. Anaplastic PXA (WHO 3) is defined by brisk mitoses (5/10 HPF).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo16'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pleomorphic-xanthoastrocytoma-pxa'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Frequently carries the <b>BRAF^V600E</b> mutation (5060% of cases).
IDH-wildtype. No 1p/19q co-deletion.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo16'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pleomorphic-xanthoastrocytoma-pxa'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN>
GFAP positive. Often strong CD34 immunostaining in tumor and adjacent brain,
similar to gangliogliomas.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo16'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pleomorphic-xanthoastrocytoma-pxa'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Complete surgical resection is the primary treatment and can be
curative for grade 2 PXA. If resected, often no further therapy is needed aside
from monitoring. If incompletely resected or if anaplastic features, adjuvant
therapy is considered. <b>Chemotherapy:</b> Because of BRAF^V600E, targeted
therapy (dabrafenib  trametinib) is a potential option for recurrence or
unresectable tumors. Traditional chemo (temozolomide or
vincristine/carboplatin) has been used but efficacy data is limited due to
rarity. <b>Radiation:</b> could be used for anaplastic PXA or recurrence, but
often avoided in young patients.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo16'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'><span
style='mso-bookmark:pleomorphic-xanthoastrocytoma-pxa'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Good for grade 2 PXAs (5-year survival ~90%); worse if anaplastic or
incomplete resection. Transformation to glioblastoma can occur in some cases.</span></span></span></span></span></span></p>

<span style='mso-bookmark:pleomorphic-xanthoastrocytoma-pxa'></span><span
style='mso-bookmark:X3d57c7607d8c3e7b43203972389eb9a6d5aaced'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><a
name=neuronal-and-mixed-neuronal-glial-tumors><span lang=EN>Neuronal and Mixed
Neuronal-Glial Tumors</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span lang=EN>This
group includes tumors that have mixed glial and neuronal differentiation,
common in pediatric/young patients, often presenting with seizures. Many are
WHO grade 1. Key examples: <b>Ganglioglioma</b> and <b>Dysembryoplastic
Neuroepithelial Tumor (DNET)</b>. WHO 2021 also lists newly recognized entities
like <b>Diffuse glioneuronal tumor with oligodendroglioma-like features and
nuclear clusters (DGONC)</b>, <b>Myxoid glioneuronal tumor</b>, and <b>Multinodular
and vacuolating neuronal tumor (MVNT)</b></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Infant,amplified"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span lang=EN>[13]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'></span></span></span></span></a><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Diffuse%20glioneuronal%20tumor%20with%20oligodendroglioma,provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span lang=EN>[14]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span lang=EN>.</span></span></span></span></span></p>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><a
name=ganglioglioma><span lang=EN>Ganglioglioma</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:ganglioglioma'><span lang=EN>Ganglioglioma (GG) is a common
mixed neuronal-glial tumor (WHO grade 1) typically seen in children and young
adults, often presenting with seizures. It most often occurs in the temporal
lobe.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo17'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:ganglioglioma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> By definition, it contains both neoplastic ganglion cells (neuronal
component) and neoplastic glial cells (usually astrocytic). Often there is a
dysplastic architecture. Calcifications can be present. If significant mitoses
or anaplasia in glial component, it could be designated anaplastic
ganglioglioma (WHO 3).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo17'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:ganglioglioma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> ~2050% have <i>BRAF^V600E</i> mutations. No IDH mutation.
Occasionally FGFR1 mutations or duplication. CDKN2A deletion can be seen in
anaplastic cases.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo17'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:ganglioglioma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN>
Neuronal markers (synaptophysin, NeuN) highlight the ganglion cells; GFAP
highlights the glial component. CD34 often positive in tumor and surrounding
cortex (similar to PXA).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo17'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:ganglioglioma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical:</span></b><span
lang=EN> Often longstanding seizures; imaging shows a cystic and solid cortical
mass, often with calcifications and variable enhancement.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo17'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:ganglioglioma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Surgical resection is usually curative for low-grade ganglioglioma and
often also controls epilepsy. If completely resected, 10-year survival &gt;90%.
If incompletely resected or progressive, options include re-operation or
adjuvant therapy. <b>Chemotherapy:</b> not standard but regimens for pLGG
(carboplatin/vincristine) have been used in unresectable cases. <b>Targeted
therapy:</b> <i>BRAF^V600E</i> mutated cases might respond to BRAF  MEK
inhibitors if needed. Radiation is reserved for rare malignant transformations
or refractory cases.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo17'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:ganglioglioma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Excellent for grade 1; anaplastic gangliogliomas have a less favorable
outcome (but still better than diffuse high-grade gliomas).</span></span></span></span></span></span></p>

<span style='mso-bookmark:ganglioglioma'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><a
name=X902756117527ef83fcf6a6dee44116745d48044><span lang=EN>Dysembryoplastic
Neuroepithelial Tumor (DNET)</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:X902756117527ef83fcf6a6dee44116745d48044'><span lang=EN>DNET
is a benign glioneuronal tumor (WHO grade 1) classically associated with
childhood epilepsy. It typically occurs in the cortex (often temporal lobe) and
is often superficial.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo18'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:X902756117527ef83fcf6a6dee44116745d48044'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> The classic form shows specific glioneuronal elements with columnar
arrangement of oligodendroglia-like cells floating in mucinous pools, with
interspersed floating neurons. It has a specific architecture reflecting a
developmental lesion. It is usually low cellularity.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo18'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:X902756117527ef83fcf6a6dee44116745d48044'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Typically no recurrent single driver mutation (usually <i>BRAF</i> is
wildtype in classic DNET). Some DNET-like tumors may have FGFR1 mutations or
BRAF alterations, but classic DNET is genetically quiet. It is thought to be a
malformative tumor.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo18'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:X902756117527ef83fcf6a6dee44116745d48044'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN>
Neuronal markers highlight the scattered neurons; glial component is GFAP
positive.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo18'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:X902756117527ef83fcf6a6dee44116745d48044'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical:</span></b><span
lang=EN> Presents with longstanding, drug-resistant focal seizures in a child
or adolescent. MRI often shows a cortical lesion with multinodular bright T2
signal and little to no enhancement (sometimes called a bubbly cortex
lesion).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo18'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:X902756117527ef83fcf6a6dee44116745d48044'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Surgical removal typically cures the epilepsy and is curative for the
tumor. These do not usually recur if completely excised. Adjuvant therapy is
not needed for classic DNET.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo18'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:X902756117527ef83fcf6a6dee44116745d48044'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Excellent (essentially benign).</span></span></span></span></span></span></p>

<span style='mso-bookmark:X902756117527ef83fcf6a6dee44116745d48044'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><a
name=Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4><span lang=EN>Diffuse
Glioneuronal Tumor with Oligodendroglioma-like Features and Nuclear Clusters
(DGONC)</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'><span lang=EN>DGONC
is a provisional new entity (WHO 2021) seen in children. It was previously
colloquially called CNS neuroepithelial tumor with oligodendroglioma-like
features and nuclear clusters (also known by an acronym CNS NET-O or
HGNET-O).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo19'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> It shows diffuse infiltration with cells that resemble
oligodendroglioma (round nuclei, clear cytoplasm) and characteristic nuclear
clusters (clusters of cells without intervening cytoplasm). It lacks the
1p/19q codeletion of true oligodendrogliomas and occurs in children.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo19'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Frequently associated with <b>MN1</b> gene alterations (e.g. MN1-BEND2
fusion)  in fact it is sometimes referred to as MN1-altered glioneuronal tumor</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L906%20the%20table%3A,positive"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'><span lang=EN>[15]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'><span lang=EN>.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo19'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN>
Mixed neuronal-glial; can have some synaptophysin positivity and GFAP for glial
cells. Often CD34 positive.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo19'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Behavior:</span></b><span
lang=EN> Considered an intermediate-grade neoplasm (not clearly grade 1, often
behaves as grade 23).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo19'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Due to rarity, there is no standard established. Surgery followed by
observation or adjuvant therapy if residual. Some have indolent course, others
can progress.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo19'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Not fully defined; likely variable.</span></span></span></span></span></span></p>

<span style='mso-bookmark:Xa6ea19dc174fc34ed604fa65ef46213bc05b9c4'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><a
name=other-rare-low-grade-neuronal-tumors><span lang=EN>Other Rare Low-Grade
Neuronal Tumors</span></a></span></span></span></span></h4>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo20'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:other-rare-low-grade-neuronal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Myxoid Glioneuronal Tumor:</span></b><span
lang=EN> A newly characterized tumor (WHO 2021) often in septum pellucidum or
periventricular region. It has a myxoid matrix and both glial and neuronal
features. It often carries an <b>PDGFRA</b> mutation or FGFR1 alteration.
Behavior is indolent (likely grade 12).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo20'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:other-rare-low-grade-neuronal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Multinodular and Vacuolating
Neuronal Tumor (MVNT):</span></b><span lang=EN> A peculiar lesion usually found
incidentally in adults (sometimes in adolescents). Appears as multiple nodules
in subcortical white matter with prominent vacuolation. Its probably a
hamartomatous lesion; often just observed. WHO 2021 lists it, but its often
not surgically removed unless needed.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo20'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:other-rare-low-grade-neuronal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Rosette-forming Glioneuronal
Tumor (RGNT):</span></b><span lang=EN> Occurs in the fourth ventricle region
(often cerebellar vermis) of young adults. Has both glial and neuronal
rosettes. Typically grade 1. Treated with surgery; good prognosis.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo20'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'><span
style='mso-bookmark:other-rare-low-grade-neuronal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Central Neurocytoma:</span></b><span
lang=EN> Predominantly in young adults (ventricular tumor of neuronal cells).
Rare in children but can occur in older adolescents. Typically WHO 2, treated
with surgery  radiation.</span></span></span></span></span></span></p>

<span style='mso-bookmark:other-rare-low-grade-neuronal-tumors'></span><span
style='mso-bookmark:neuronal-and-mixed-neuronal-glial-tumors'></span><span
style='mso-bookmark:X0af533689dcb0b9ec304f3da0c1376144cc4488'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=pediatric-high-grade-gliomas><span
lang=EN>Pediatric High-Grade Gliomas</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>Pediatric high-grade gliomas (pHGG) include various aggressive
astrocytic tumors (WHO grade 3 and 4) arising in children. They behave
aggressively and, unlike adult glioblastomas, have distinct biology (often lack
IDH mutation, and many have pediatric-specific mutations like H3 histone
mutations)</span></span></span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=also%20revealed%20important%20dif%EF%BF%BEferences%20between,While%20targeted%20therapy%20trials"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[2]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. Historically, pediatric HGG outcomes have been poor, making them the
leading cause of cancer-related mortality in children</span></span></span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=Pediatric%20brain%20tumors%20are%20the,These%20findings%20have"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[16]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. WHO 2021 created a category pediatric-type diffuse high-grade
gliomas separate from adult types</span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Pediatric,wildtype"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[17]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. Major entities are: <b>Diffuse midline glioma, H3 K27-altered;
Diffuse hemispheric glioma, H3 G34-mutant; Diffuse pediatric-type high-grade
glioma, H3-wildtype and IDH-wildtype;</b> and <b>Infant-type hemispheric glioma</b></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Pediatric,wildtype"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[18]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Polymorphous%20low,Myxoid%20glioneuronal%20tumor"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[19]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. Additionally, some high-grade astrocytomas with unique features (like
<i>piloid</i> features) are recognized. Common clinical presentation for pHGG
is subacute neurologic decline (raised intracranial pressure, focal deficits,
seizures depending on location).</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><b><span
lang=EN>Diagnostic criteria:</span></b><span lang=EN> High-grade gliomas are
defined histologically by high cellularity, mitotic activity, microvascular
proliferation and/or necrosis (which would classify it as WHO grade 4
glioblastoma). In children, molecular features are crucial: e.g. presence of
H3K27M (now H3 K27-altered) defines a specific diffuse midline glioma entity</span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=information,35%20Astroblastoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[20]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><b><span
lang=EN>Predisposition:</span></b><span lang=EN> Unlike adult GBM (where prior
radiation or germline conditions are rare causes), a notable fraction of pHGGs
occur in children with predispositions like Neurofibromatosis type 1,
Li-Fraumeni syndrome (germline TP53), or Constitutional MMR deficiency (Lynch
syndrome variant)</span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=predisposition%20syndromes%2C%20including%20neurofibromatosis%20type,grade%20gliomas"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[21]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. For example, NF1 patients can develop high-grade astrocytomas, and
biallelic mismatch repair mutation carriers often develop childhood
glioblastomas</span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=predisposition%20syndromes%2C%20including%20neurofibromatosis%20type,grade%20gliomas"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[21]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><b><span
lang=EN>Treatment:</span></b><span lang=EN> <b>Multidisciplinary management</b>
is needed. Standard approach (if trial unavailable) is maximal safe resection,
followed by focal radiation therapy and adjuvant chemotherapy</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20High%20Grade%20Glioma%20Overview%3A,pdf%20page%205%20of%2015"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[22]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. The Childrens Oncology Group trial <b>ACNS0423</b> established a
chemo-radiation approach often used as a guideline</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=2nd%20Line%20%E2%80%A2%20Targeted%20inhibitor,with%20additional%20IT%20chemotherapy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[23]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. Typically: - <b>Surgery:</b> Aim for maximal resection of tumor when
location permits (except intrinsic brainstem lesions like DIPG where resection
is not feasible). Even partial debulking is thought to help symptoms and
possibly survival</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20High%20Grade%20Glioma%20Overview%3A,pdf%20page%205%20of%2015"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[22]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. - <b>Radiation:</b> Conventional focal radiation ~5460 Gy in 1.82
Gy fractions to the tumor bed is standard for children 3 years</span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%1750.4%E2%80%9354%20Gy%20with%20a%20cone,to%2054%20and%2060%20Gy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[24]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. For example, a dose of 54 Gy in 30 fractions is typical for
supratentorial HGG</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Maximal%20safe%20surgical,Chemotherapy%20is%20given%20as"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[25]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. Brainstem gliomas (DIPG) typically get 54 Gy to the pons</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Focal%20radiation%20therapy,common%20malignant%20brain%20tumor%20of"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[26]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. Children &lt;3 are often spared radiation initially due to severe
long-term effects; chemo is used to delay radiation. - <b>Chemotherapy:</b>
Pediatric HGG chemotherapy often mirrors adult regimens (e.g. <b>temozolomide
(TMZ)</b> given daily during RT and for 612 cycles after). However, clinical
trials have explored adding agents like <b>lomustine</b> or <b>vincristine</b>.
COG ACNS0423 evaluated TMZ-based chemoradiation; earlier CCG trials (e.g.
CCG-945) used adjuvant CCNU/VCR/Prednisone without clear survival benefit</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20High%20Grade%20Glioma%20Overview%3A,pdf%20page%205%20of%2015"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>[22]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>. Recent trends include incorporating targeted therapy if a driver is
known (e.g. BRAF^V600E mutant HGG treated with BRAF/MEK inhibitors on trial). -
<b>Clinical Trials:</b> Enrollment is strongly encouraged, given poor outcomes.
Trials targeting histone mutations or using immunotherapy (checkpoint
inhibitors, oncolytic viruses) are ongoing.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><b><span
lang=EN>Prognosis:</span></b><span lang=EN> Generally poor. The 5-year survival
for pediatric glioblastoma remains under 20% in most series. One subset with
better outcome are infants with certain gene fusions (see below) and perhaps
those amenable to total resection, but overall, outcomes lag behind other
pediatric tumors.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
lang=EN>Below are specific entities:</span></span></span></span></p>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><a
name=X6e50780403ca1edb68ccef105477012f967f269><span lang=EN>Pediatric-type
Diffuse High-Grade Gliomas</span></a></span></span></span></h3>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><a
name=Xba332aac03655841400cb310ce2c7248849ace3><span lang=EN>Diffuse Midline
Glioma, H3 K27-altered (DIPG)</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><b><span lang=EN>Diffuse
midline glioma, H3 K27-altered</span></b><span lang=EN> is defined by a
characteristic <b>H3 K27M mutation</b> in one of the histone H3 genes
(typically <i>H3F3A</i> or <i>HIST1H3B</i>) or alternative mechanisms that
disrupt H3K27 trimethylation</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=information,35%20Astroblastoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>[20]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>.
This entity most classically presents as the intrinsic pontine glioma (DIPG) in
children, but can also occur in other midline structures (thalamus, spinal
cord).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo21'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Location/Clinical:</span></b><span
lang=EN> Often in the pons (DIPG), affecting children around 510 years old.
Presents with brainstem signs: cranial nerve palsies, long tract signs, ataxia.
DIPG is diagnosed radiologically (expansile T2 hyperintense pontine lesion)
since biopsy is often not done (though now sometimes done for trials). Thalamic
or spinal cord H3 K27M gliomas cause corresponding focal deficits.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo21'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> High-grade infiltrative astrocytoma. May show indistinct histologic
features (could appear as anaplastic astrocytoma or GBM); the defining feature
is the molecular alteration. <i>WHO grade is 4</i> by definition due to its
behavior, even if histology is moderate</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=confuse%20clinical%20care%20,current%20therapeutic%20regi%EF%BF%BEmens%20such%20that"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>[27]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'></span></span></span></span></span></a><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=embryonal%20tumor%20that%20has%20an,current%20therapeutic%20regi%EF%BF%BEmens%20such%20that"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>[28]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo21'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> <b>H3 K27M</b> mutation leads to global reduction of H3K27
trimethylation (loss of H3K27me3 on IHC). WHO 2021 uses H3 K27-altered to
allow for non-mutational mechanisms (e.g. overexpression of EZHIP in some
midline tumors) that have same effect</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=information,35%20Astroblastoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>[20]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'></span></span></span></span></span></a><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=the%20diffuse%20midline%20glioma%20is,35%20Astroblastoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>[29]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>.
Often co-occurs with TP53 mutations and ACVR1 mutations (the latter especially
in DIPG). ATRX loss is common in thalamic cases.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo21'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN>
Loss of H3K27me3 staining in tumor nuclei is a diagnostic surrogate marker</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L463%20Supratentorial%20ependymomas,activated%20CTNNB1%2C%20APC"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>[30]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>.
GFAP typically positive (glial).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo21'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> <b>Radiation therapy</b> is the mainstay for DIPG  54 Gy in 30
fractions to the pons provides transient palliation</span></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Focal%20radiation%20therapy,common%20malignant%20brain%20tumor%20of"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>[26]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>.
It improves symptoms and possibly short-term survival but is not curative. No
chemotherapy has proven effective for DIPG; numerous trials (EGFR inhibitors,
ACVR1 inhibitors, checkpoint inhibitors, ONC201 etc.) are ongoing. Standard
chemotherapy (TMZ or others) has not clearly extended survival. For non-pontine
midline gliomas (thalamic/spinal), maximal resection might be attempted if
feasible (rarely possible in thalamus), followed by chemoradiation as per other
HGG.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo21'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Dismal in DIPG  median survival ~912 months. 2-year survival
&lt;10%. Non-pontine midline H3K27M gliomas also fare poorly, though a subset
(spinal cord) may live longer if lower-grade histology.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo21'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Note:</span></b><span lang=EN>
Because of the uniformly poor outcome, DIPG is often handled as a distinct
entity. <b>Focal RT</b> is considered the standard of care</span></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=VCR%2FCarboplatin%20,with%20additional%20IT%20chemotherapy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>[31]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>.
In the Canadian consensus, DIPG recommendation is just focal RT, acknowledging
lack of effective chemo</span></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=VCR%2FCarboplatin%20,with%20additional%20IT%20chemotherapy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>[31]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'><span lang=EN>.
Clinical trials (like PNOC or BIOMEDE) are exploring targeted agents.</span></span></span></span></span></span></p>

<span style='mso-bookmark:Xba332aac03655841400cb310ce2c7248849ace3'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><a
name=diffuse-hemispheric-glioma-h3-g34-mutant><span lang=EN>Diffuse Hemispheric
Glioma, H3 G34-mutant</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:diffuse-hemispheric-glioma-h3-g34-mutant'><span lang=EN>This
is another specific molecular entity: pediatric high-grade gliomas in the
cerebral hemispheres with an <b>H3F3A G34R/V</b> mutation
(glycine-to-arginine/valine at position 34 of H3.3).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo22'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:diffuse-hemispheric-glioma-h3-g34-mutant'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Epidemiology:</span></b><span
lang=EN> Occur in older children and adolescents, typically in the cerebral
cortex. Often present with seizures (due to cortical location).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo22'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:diffuse-hemispheric-glioma-h3-g34-mutant'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> High-grade astrocytic tumor (often grade 4 glioblastoma morphology).
Can have large bizarre nuclei and multinucleated cells; often significant
necrosis and microvascular proliferation.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo22'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:diffuse-hemispheric-glioma-h3-g34-mutant'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Defined by <b>H3.3 G34</b> mutation. These tumors frequently have
co-mutations in TP53 and ATRX (somewhat resembling the profile of adult
IDH-wildtype GBM except for the H3 mutation). They do <i>not</i> have IDH
mutations (mutually exclusive).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo22'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:diffuse-hemispheric-glioma-h3-g34-mutant'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN>
No specific immunohistochemical surrogate for G34R/V is widely used clinically
(unlike K27M). ATRX loss and p53 positivity are common.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo22'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:diffuse-hemispheric-glioma-h3-g34-mutant'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Similar approach as other HGG  surgical resection if possible,
followed by focal radiation (typically ~60 Gy) and adjuvant chemotherapy (e.g.
TMZ). No tailored therapy yet for H3G34.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo22'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:diffuse-hemispheric-glioma-h3-g34-mutant'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Poor, though possibly slightly better than DIPG. These are aggressive
tumors with median survival on the order of 13 years in reports.</span></span></span></span></span></span></p>

<span style='mso-bookmark:diffuse-hemispheric-glioma-h3-g34-mutant'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><a
name=X497ff99086d7d9c1f18b25f44abf3a1cf9fae91><span lang=EN>Diffuse Pediatric
High-Grade Glioma, H3/IDH-wildtype</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:X497ff99086d7d9c1f18b25f44abf3a1cf9fae91'><span lang=EN>This
category covers pediatric diffuse high-grade gliomas that lack both H3
mutations and IDH1/2 mutations</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Pediatric,wildtype"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:X497ff99086d7d9c1f18b25f44abf3a1cf9fae91'><span lang=EN>[17]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:X497ff99086d7d9c1f18b25f44abf3a1cf9fae91'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:X497ff99086d7d9c1f18b25f44abf3a1cf9fae91'><span lang=EN>.
Essentially it is a diagnosis of exclusion for pediatric GBM-like tumors that
dont fit the other molecularly-defined groups (and are not the infant type,
see below). These would have been called GBM, IDH-wildtype in an older
scheme, but in a child under 18 they fall here if no H3 mutation.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo23'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:X497ff99086d7d9c1f18b25f44abf3a1cf9fae91'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Examples:</span></b><span
lang=EN> A GBM in a 10-year-old that is H3 wildtype, IDH wildtype. Some of
these may have other alterations like EGFR amplification, TERT promoter
mutation, etc., but those are more common in adults. Others may have novel
pediatric drivers (e.g. <i>MET</i> fusions).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo23'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:X497ff99086d7d9c1f18b25f44abf3a1cf9fae91'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> High-grade (WHO 4) features: necrosis and/or microvascular
proliferation, or at least anaplastic astrocytoma features with high mitotic
count.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo23'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:X497ff99086d7d9c1f18b25f44abf3a1cf9fae91'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> By definition IDH-wt, H3-wt. They might have PTEN loss, CDKN2A/B
deletions, or other genetic changes. If they have EGFR amp or TERT promoter
mut, biologically they are like adult GBM, but those changes are less frequent
in young children.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo23'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:X497ff99086d7d9c1f18b25f44abf3a1cf9fae91'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Maximal surgery + RT + TMZ (following adult GBM paradigm) is generally
used if childs age permits. Clinical trials are strongly considered.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo23'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:X497ff99086d7d9c1f18b25f44abf3a1cf9fae91'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Very poor (median survival ~1 year or less if true GBM). Some younger
children in this category might actually have better outcomes if they carry
unusual fusions (e.g. NTRK)  those might be reclassified as infant-type or
other emerging subgroups as understanding improves.</span></span></span></span></span></span></p>

<span style='mso-bookmark:X497ff99086d7d9c1f18b25f44abf3a1cf9fae91'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><a
name=infant-type-hemispheric-glioma><span lang=EN>Infant-Type Hemispheric
Glioma</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:infant-type-hemispheric-glioma'><span lang=EN>This is a
newly recognized subset of high-grade gliomas occurring in infants (typically
&lt;13 years old) that have characteristic gene fusions and surprisingly
better outcomes than usual HGG. WHO 2021 lists Infant-type hemispheric glioma
as a distinct entity</span></span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Diffuse%20hemispheric%20glioma%2C%20H3%20G34,grade%20astrocytoma%20with%20piloid%20features"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:infant-type-hemispheric-glioma'><span lang=EN>[32]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:infant-type-hemispheric-glioma'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:infant-type-hemispheric-glioma'><span lang=EN>.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo24'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:infant-type-hemispheric-glioma'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Common gene fusions in these tumors include <b>ETV6-NTRK3</b>, <b>ALK/ROS1
fusions</b>, and MET fusions. These are receptor tyrosine kinase fusions that
drive the tumor.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo24'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:infant-type-hemispheric-glioma'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical:</span></b><span
lang=EN> Present in infants with large hemispheric masses; often very large at
diagnosis. Despite being high-grade histologically, some infants respond
dramatically to targeted therapy.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo24'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:infant-type-hemispheric-glioma'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Aside from surgery and conventional chemo, importantly <b>targeted
inhibitors</b> (like TRK inhibitors for NTRK fusions, ALK inhibitors, etc.)
have shown striking efficacy in case reports. For example, use of larotrectinib
(TRK inhibitor) has led to tumor regression allowing avoidance of intense
chemo/radiation during infancy.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo24'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:infant-type-hemispheric-glioma'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> With modern targeted approaches, some of these infants do very well,
achieving long-term remission, in contrast to historically poor outcomes. Thus,
identifying the fusion is critical.</span></span></span></span></span></span></p>

<span style='mso-bookmark:infant-type-hemispheric-glioma'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><a
name=Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751><span lang=EN>High-Grade
Astrocytoma with Piloid Features</span></a></span></span></span></span></h4>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><span lang=EN>Another
new entity in WHO 2021, this refers to an astrocytoma that morphologically has
features of pilocytic astrocytoma (like biphasic architecture, Rosenthal
fibers) but behaves in a high-grade manner and has genetic alterations more
akin to high-grade tumors.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo25'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Often has <i>BRAF</i> alterations or TP53 mutations. Some may arise
from a PA that underwent malignant transformation.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo25'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Significance:</span></b><span
lang=EN> It highlights that even tumors that look somewhat like pilocytic can
in rare cases be aggressive; however, this is an uncommon diagnosis. Treatment
would follow HGG guidelines.</span></span></span></span></span></span></p>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><b><span lang=EN>Note:</span></b><span
lang=EN> Other uncommon pediatric high-grade tumors include anaplastic
pleomorphic xanthoastrocytoma and anaplastic ganglioglioma, but those are
variants of the low-grade entities described earlier when they show high-grade
features.</span></span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><b><span lang=EN>Treatment
Considerations and Protocols:</span></b><span lang=EN> In practice, pediatric
HGG patients (excluding DIPG) often follow protocols like ACNS0423 which used
radiation with concurrent TMZ and adjuvant TMZ/lomustine</span></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20The%20approach%20includes,8%20Gy%20with%20concurrent"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><span lang=EN>[33]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><span lang=EN>.
The <b>Canadian consensus</b> indicates using chemotherapy/radiation per
ACNS0423 for pediatric HGG</span></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=2nd%20Line%20%E2%80%A2%20Targeted%20inhibitor,with%20additional%20IT%20chemotherapy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><span lang=EN>[23]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><span lang=EN>.
For children &lt;3, a common strategy is high-dose chemotherapy regimens to
delay radiation (e.g. the Baby POG/Head Start protocols using multiple chemo
agents with stem cell rescue). Incorporation of molecular targeted therapy is
on the horizon for cases with identifiable targets</span></span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=MS,Subsequent"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><span lang=EN>[34]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'></span></span></span></span></span></a><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=multidisciplinary%20team%20with%20experience%20managing,will%20address%20additional%20tumor%20types"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><span lang=EN>[35]</span></span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'></span></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pediatric-high-grade-gliomas'><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'><span
style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'><span lang=EN>.
Unfortunately, recurrence is common in pHGG and salvage options are limited
(clinical trials or re-irradiation for focal recurrences might be attempted).
Palliative care is an important facet of management given outcomes.</span></span></span></span></span></span></p>

<span style='mso-bookmark:Xa93b5eac0b3d6373d8eb32c2bf4e2238eb47751'></span><span
style='mso-bookmark:X6e50780403ca1edb68ccef105477012f967f269'></span><span
style='mso-bookmark:pediatric-high-grade-gliomas'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=ependymal-tumors><span lang=EN>Ependymal
Tumors</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>Ependymomas are glial tumors arising from ependymal lining cells of the
ventricular system or central canal. They can occur anywhere in CNS, but in
children, common locations are the <b>posterior fossa</b> (fourth ventricle)
and <b>supratentorial</b> (cerebral ventricular region). Spinal cord
ependymomas are more common in adults (except NF2 teens). Pediatric ependymomas
are usually WHO grade 2 or 3 and tend to recur locally. The 2021 WHO
classification revolutionized ependymoma classification by incorporating site
and molecular profile: ependymomas are now classified by <b>anatomic site and
molecular subgroup</b></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Ependymomas,molecular%20groups%20across%20the%20supratentorial"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[36]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L1248%20ependymoma%2C%20group,pdf%20page%2017%20of%2021"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[37]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>:</span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo26'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Supratentorial ependymoma</span></b><span
lang=EN>  subdivided into <b>ZFTA fusion-positive</b> (ZFTA is same as
C11orf95 fusion, historically called RELA-fusion ependymoma) and <b>YAP1
fusion-positive</b></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Supratentorial%20ependymoma%20Supratentorial%20ependymoma%2C%20ZFTA,positive%20Posterior%20fossa%20ependymoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[38]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>.</span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo26'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Posterior fossa ependymoma</span></b><span
lang=EN>  subdivided into <b>Group PFA</b> and <b>Group PFB</b> based on
methylation profiling</span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L248%20Posterior%20fossa,amplified"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[39]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>.</span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo26'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Spinal ependymoma</span></b><span
lang=EN>  includes <b>MYCN-amplified</b> subtype versus others</span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Posterior%20fossa%20ependymoma%2C%20group%20PFA,amplified"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[40]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>.</span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo26'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Classic histologic variants
(cellular, clear cell, papillary) are no longer separate entities, just
patterns</span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=now%20understood%20to%20be%20similar,Papillary%2C%20clear%20cell%2C%20and"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[41]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L1270%20subtypes%20of,clinicopathological%20utility%20of%20grading%20ependymal"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[42]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>. WHO grades: subependymoma (grade 1), myxopapillary (now grade 2)</span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L1265%20classifications%2C%20the,Papillary%2C%20clear%20cell%2C%20and"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[43]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>, other ependymomas can be grade 2 or 3.</span></span></span></span></p>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><b><span
lang=EN>Diagnostic features:</span></b><span lang=EN> Ependymomas show
characteristic perivascular pseudorosettes (tumor cells arranged around blood
vessels with an intervening zone of processes) and sometimes true ependymal
rosettes. They may calcify. Anaplastic ependymoma (grade 3) shows increased
cell density, mitoses, and microvascular proliferation, but grading
reproducibility is an issue</span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=subtypes%20of%20ependymoma%2C%20being%20included,clinicopathological%20utility%20of%20grading%20ependymal"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[44]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=ependymoma%E2%80%9D%20is%20no%20longer%20listed,according%20to%20its%20histopathological%20features"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[45]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>. WHO now does <i>not</i> mandate a grade in the integrated diagnosis
of molecularly-defined ependymomas, but histologically one can still assign
grade 2 vs 3 if desired</span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L1281%20ependymoma%E2%80%9D%20is,according%20to%20its%20histopathological%20features"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[46]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><b><span
lang=EN>Clinical:</span></b><span lang=EN> Posterior fossa ependymomas
(typically PFA) often present in young children (&lt;5 years) with signs of
raised intracranial pressure (headache, vomiting, ataxia). Supratentorial
ependymomas present with seizures or focal deficits depending on location. Drop
metastases can occur (via CSF spread), though less common than in
medulloblastoma.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><b><span
lang=EN>Treatment:</span></b><span lang=EN> The cornerstone is <b>maximal
surgical resection</b>. Ependymomas are relatively radioresistant, so a gross
total resection greatly improves outcome. Post-operative <b>radiation therapy</b>
is standard for patients &gt;1218 months old: - For localized ependymoma, <b>focal
irradiation</b> to the tumor bed is recommended (craniospinal irradiation is
not routinely done unless there is confirmed CSF dissemination, which is rare
at diagnosis). Dose typically <b>5459.4 Gy</b> to the resection cavity region</span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%1750.4%E2%80%9354%20Gy%20with%20a%20cone,to%2054%20and%2060%20Gy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[24]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>. Photon or proton conformal therapy can be used to spare normal
tissue. - Children &lt;3 years: often initial approach is surgery + <b>chemotherapy</b>
to delay radiation until the child is older. Chemotherapy (e.g. regimens with
vincristine, carboplatin, etoposide, cyclophosphamide  like the COG ACNS1221
or earlier Baby Brain protocols) can cause temporary responses, allowing some
delay of RT. - <b>Chemotherapy:</b> Unlike medulloblastoma, chemo is less
effective in ependymoma. Its role is mainly in infants or in recurrence.
Ependymomas generally do not have a standard chemo that improves cure rate
after surgery+RT; trials have not shown clear benefit of adjuvant chemo in
older children. However, in recurrence, a regimen like TMZ or a platinum-based
chemo might be tried. - <b>Targeted therapy:</b> No established targeted agents
yet, but research ongoing (some supratentorial RELA-fused ependymomas
overexpress certain pathways that could be targeted, and MEK inhibitors were
tried in trials for recurrent ependymoma with limited success</span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=match%20at%20L4821%20exhibited%20a,only%20one%20hospitalization%20for%20neutropenic"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[47]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>). - <b>NCCN Guidelines</b> emphasize maximal resection and radiation;
chemotherapy is optional or trial-based in older kids. European protocols often
avoid delaying radiation beyond 1215 months of age because local control is
critical.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><b><span
lang=EN>Outcome:</span></b><span lang=EN> Prognosis is intermediate. 5-year
survival is ~5070% for localized ependymoma with gross total resection and
radiation. PFA type (infant posterior fossa) has worse prognosis than PFB
(which often occurs in slightly older children)</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=In%20certain%20tumors%2C%20the%20molecular,in%20a%20variety%20of%20tumors"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>[48]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>. Molecular grouping correlates: PFA ependymomas often recur (even
after seemingly good resection) and have poorer outcome, whereas PFB has better
outcomes in some studies. Supratentorial YAP1-fused ependymomas (often in young
children) may have favorable outcomes, whereas ZFTA(C11orf95)-fusion
ependymomas are more aggressive.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
lang=EN>Now specifics by subtype:</span></span></span></span></p>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><a
name=X4779106ecf74580986070de4fc8470282b6f40a><span lang=EN>Supratentorial
Ependymoma (ZFTA fusion-positive &amp; YAP1 fusion-positive)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><b><span lang=EN>Supratentorial
ependymomas</span></b><span lang=EN> (ST-EPN) arise in the cerebral hemispheres
(often cortical or deep, sometimes large). Two major molecular subtypes: - <b>ZFTA
fusionpositive:</b> formerly known as RELA-fusion ependymoma (C11orf95-RELA
fusion first described). ZFTA (C11orf95) is a gene that fuses with RELA or
other partners. This subtype is the most common supratentorial ependymoma in
children</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=supratentorial%20ependymoma%3A%20one%20with%20ZFTA,fusion%20and%20another"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><span lang=EN>[49]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><span lang=EN>.
Tends to present in kids around 510 years. Its usually WHO grade 3
histologically. These are aggressive. - <b>YAP1 fusionpositive:</b> less
common, seen in younger patients sometimes. YAP1-MAMLD1 is a fusion example.
May have a different clinical behavior (somewhat better, possibly corresponding
to what was balanced genomic subtype).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><b><span lang=EN>Diagnosis:</span></b><span
lang=EN> Histologically, ST ependymomas look similar to other ependymomas
(pseudorosettes etc.). The fusion is identified by molecular testing.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><b><span lang=EN>Treatment:</span></b><span
lang=EN> Surgical resection is often challenging due to location, but goal is
GTR. After surgery, focal RT to ~59.4 Gy to residual cavity is recommended</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%1750.4%E2%80%9354%20Gy%20with%20a%20cone,to%2054%20and%2060%20Gy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><span lang=EN>[24]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><span lang=EN>.
For ZFTA-fused, some trials consider chemotherapy (e.g. using pediatric
HGG-type regimens) but unclear benefit. According to Canadian consensus, for
localized ependymoma (which includes supratentorial), the recommended therapy
is surgery followed by focal radiation only</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=HR%20%E2%80%A2%20Chemotherapy%20per%2099703,with%20WVI%20%C2%B1%20boost%20to"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><span lang=EN>[50]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><span lang=EN>.
No chemotherapy was included in consensus standard outside trials</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=HR%20%E2%80%A2%20Chemotherapy%20per%2099703,with%20WVI%20%C2%B1%20boost%20to"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><span lang=EN>[50]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'><b><span lang=EN>Outcome:</span></b><span
lang=EN> ZFTA-fusion ependymomas have high relapse rates and ~5-year survival
around 50%. YAP1-fusion ependymomas possibly have better outcomes (data limited
due to rarity). Surveillance imaging for relapse (especially local) is done
frequently in first 23 years post-treatment.</span></span></span></span></span></p>

<span style='mso-bookmark:X4779106ecf74580986070de4fc8470282b6f40a'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><a
name=posterior-fossa-ependymoma-group-pfa-pfb><span lang=EN>Posterior Fossa
Ependymoma (Group PFA &amp; PFB)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'><span lang=EN>Posterior
fossa ependymomas (PF-EPN) arise in the 4th ventricle region. WHO 2021
separates: - <b>Group PFA:</b> Posterior fossa ependymoma group A  typically
infants and young children. These have a distinct epigenetic profile (often
with high EZHIP protein expression causing epigenetic dysregulation)</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Supratentorial%20ependymomas%20ZFTA%2C%20RELA%2C%20YAP1%2C,activated%20CTNNB1%2C%20APC"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'><span lang=EN>[51]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'><span lang=EN>.
More aggressive. - <b>Group PFB:</b> Group B  tends to occur in older children
or adolescents, with a different methylation profile and generally better
prognosis.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'><b><span lang=EN>Diagnosis:</span></b><span
lang=EN> PF ependymomas often show moderate-to-densely cellular tumors with
ependymal pseudorosettes. Sometimes PFA tumors can appear less differentiated.
There is no easy immunohistochemical test for PFA vs PFB, though PFA often
shows loss of H3K27me3 similar to K27M gliomas due to EZHIP overexpression, but
thats not specific enough clinically.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'><b><span lang=EN>Treatment:</span></b><span
lang=EN> Aggressive surgical resection is critical. Because these sit in the
4th ventricle, involvement of brainstem structures can limit resection.
Post-op, all patients (if &gt;1218 months) should get <b>focal radiation</b>
to the tumor bed (typically 5459.4 Gy)</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%1750.4%E2%80%9354%20Gy%20with%20a%20cone,to%2054%20and%2060%20Gy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'><span lang=EN>[24]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'><span lang=EN>.
If child is too young (&lt;1), some will attempt chemo for a period and later
do RT. No CSI unless disseminated. Chemotherapy after radiation has not
definitively shown benefit, but some protocols give adjuvant chemo (e.g. PDECT
regimen) especially if residual disease, though its not standard. European
trial results (e.g. SIOP Ependymoma II) are pending to clarify chemo benefit.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'><b><span lang=EN>Outcome:</span></b><span
lang=EN> PFA ependymomas have high risk of recurrence; 5-year PFS may be only
~40%. PFB ependymomas can have 5-year PFS ~75% in some series. Recurrences are
typically local (around the resection site). Salvage therapy might include
re-resection, re-irradiation, or experimental therapies.</span></span></span></span></span></p>

<span style='mso-bookmark:posterior-fossa-ependymoma-group-pfa-pfb'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><a
name=X832a1fe6d1388e01cd47d638e56de92915abbe6><span lang=EN>Spinal Ependymoma
(incl. MYCN-amplified subtype)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'><span lang=EN>Spinal
cord ependymomas in children are rare (except in NF2 patients). They include: -
<b>Conventional spinal ependymoma</b> (usually WHO grade 2)  often
intramedullary in cervical or thoracic cord. - <b>Myxopapillary ependymoma</b>
 occurs in filum terminale (see below), traditionally grade 1 but now upgraded
to grade 2</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L1265%20classifications%2C%20the,Papillary%2C%20clear%20cell%2C%20and"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'><span lang=EN>[43]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'><span lang=EN>. -
<b>Spinal ependymoma, MYCN-amplified</b>  a very aggressive subtype recently
recognized in children/adolescents, often cervical, with MYCN gene
amplification</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Multinodular%20and%20vacuolating%20neuronal%20tumor,mutant"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'><span lang=EN>[52]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'><span lang=EN>.
This behaves like a high-grade malignancy.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'><b><span lang=EN>Clinical:</span></b><span
lang=EN> Back pain, motor/sensory signs depending on level. MRI shows an
intramedullary enhancing cord lesion (for myxopapillary, a filum mass often
with drop mets).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'><b><span lang=EN>Treatment:</span></b><span
lang=EN> <b>Surgery</b> is first-line. For fully resected grade 2 spinal
ependymoma, observation can be considered. For subtotally resected or any
high-grade features, <b>radiation</b> to involved spinal levels (typically
~5054 Gy) is recommended. The MYCN-amplified subtype likely merits post-op
radiation and maybe chemo similar to HGG due to its aggressive nature.
Myxopapillary ependymomas (even though now grade 2) are often cured by
resection, but if residual or if CSF seeding, radiation or CSI might be used.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'><b><span lang=EN>Outcome:</span></b><span
lang=EN> Conventional spinal ependymomas have good prognosis, especially if
resected (many are cured). MYCN-amplified ones have poor outcomes (tend to
recur early and disseminate). NF2-associated ependymomas (often multiple) can
be an ongoing issue but are usually manageable individually.</span></span></span></span></span></p>

<span style='mso-bookmark:X832a1fe6d1388e01cd47d638e56de92915abbe6'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><a
name=myxopapillary-ependymoma><span lang=EN>Myxopapillary Ependymoma</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:myxopapillary-ependymoma'><span lang=EN>A variant typically
occurring in the <b>filum terminale</b> of the spinal cord (lumbar region). It
is characterized by cuboidal tumor cells in papillary arrangements in a myxoid
background with blood vessels.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo27'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:myxopapillary-ependymoma'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>WHO grade:</span></b><span
lang=EN> Now considered grade 2 (was grade 1) because they can recur or drop
metastasize</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L1265%20classifications%2C%20the,Papillary%2C%20clear%20cell%2C%20and"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:myxopapillary-ependymoma'><span lang=EN>[43]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:myxopapillary-ependymoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:myxopapillary-ependymoma'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo27'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:myxopapillary-ependymoma'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical:</span></b><span
lang=EN> Presents in young adults (20s) more commonly, with low back pain or
sciatica. Rare in young children but can occur in adolescence.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo27'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:myxopapillary-ependymoma'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Surgical removal (often curative). If completely resected and no drop
mets, observation. If residual tumor or disseminated along CSF, consider
radiation to residual or CSI in dissemination.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo27'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:myxopapillary-ependymoma'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Very good if resected; long-term control is high, but lifelong
follow-up is needed.</span></span></span></span></span></p>

<span style='mso-bookmark:myxopapillary-ependymoma'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><a
name=subependymoma><span lang=EN>Subependymoma</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><span lang=EN>A benign, slow-growing
ependymal tumor (WHO grade 1) usually in adults (4th or lateral ventricle).
Rare in children. When present, usually incidental or causes obstruction
symptoms.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo28'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> Very low cellularity, microcystic, with clusters of ependymal nuclei
on a fibrillary background.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo28'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Often observation if small/incidental. If causing hydrocephalus,
surgical removal fixes it.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo28'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Excellent; essentially never transforms.</span></span></span></span></span></p>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><b><span lang=EN>Summary of Therapy:</span></b><span
lang=EN> The <b>NCCN pediatric CNS tumor guidelines</b> emphasize that for
ependymomas, maximal safe resection and involved-field radiation are standards</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20High%20Grade%20Glioma%20Overview%3A,943%20randomized"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><span lang=EN>[53]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'></span></span></span></span></a><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Spinal%20EPN%20%28SP,19"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><span lang=EN>[54]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><span lang=EN>. The Canadian consensus
specifically: Localized Ependymoma  Focal radiation (after surgery)</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=HR%20%E2%80%A2%20Chemotherapy%20per%2099703,with%20WVI%20%C2%B1%20boost%20to"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><span lang=EN>[50]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><span lang=EN>. No chemotherapy is listed as
standard, reflecting its limited impact</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=HR%20%E2%80%A2%20Chemotherapy%20per%2099703,with%20WVI%20%C2%B1%20boost%20to"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><span lang=EN>[50]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:ependymal-tumors'><span
style='mso-bookmark:subependymoma'><span lang=EN>.</span></span></span></span></span></p>

<span style='mso-bookmark:subependymoma'></span><span style='mso-bookmark:ependymal-tumors'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=choroid-plexus-tumors><span lang=EN>Choroid
Plexus Tumors</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'><span
lang=EN>Choroid plexus tumors originate from the choroid plexus epithelium in
the ventricles. They are most common in young children. Two main types: - <b>Choroid
Plexus Papilloma (CPP)</b>  WHO grade 1 (benign). - <b>Choroid Plexus
Carcinoma (CPC)</b>  WHO grade 3 (malignant). There is also an intermediate
atypical papilloma (grade 2) if increased mitoses but not frank carcinoma.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'><b><span
lang=EN>Clinical:</span></b><span lang=EN> Present with hydrocephalus signs due
to CSF overproduction or blockage. Often tumors in lateral ventricle (in
infants) or 4th ventricle (older kids).</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'><b><span
lang=EN>Diagnosis:</span></b><span lang=EN> Papillomas have papillary
structures with a single layer of uniform cuboidal epithelial cells. Carcinomas
show frank malignancy: cellular atypia, mitoses, brain invasion.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'><b><span
lang=EN>Molecular:</span></b><span lang=EN> Some CPCs are associated with
germline TP53 mutations (Li-Fraumeni syndrome)</span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Li,Sarcomas%2C%20adrenocortical%20carcinoma%2C%20breast%20cancer"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'><span
lang=EN>[55]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'><span
lang=EN>, which dramatically increases CPC risk in infancy. Otherwise, not many
signature mutations known, though recent data shows RB pathway involvement in
some.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'><b><span
lang=EN>Treatment:</span></b><span lang=EN> - <b>Papilloma (CPP):</b> Surgical
resection is usually curative. Hydrocephalus may resolve after resection. No
adjuvant therapy needed for CPP. - <b>Carcinoma (CPC):</b> Treatment is
aggressive. <b>Surgery:</b> Attempt gross total resection. <b>Chemotherapy:</b>
Given high propensity for spread, intensive chemo regimens are used, often
similar to infant brain tumor protocols (e.g. alternating courses of etoposide,
vincristine, cyclophosphamide, cisplatin as used in COG protocols). <b>Radiation:</b>
If child is old enough (3 years), craniospinal irradiation might be considered
due to metastatic tendency, followed by focal boost. However, because CPC often
occurs in infants, high-dose chemo with stem cell transplant has been tried to
avoid CSI. - For instance, the <b>COG trial ACNS0721</b> explored high-dose
methotrexate-based chemo for CPC. Some European protocols include CSI for CPC
in older kids. - <b>Prognosis:</b> CPP  excellent (near 100% survival if
resected). CPC  guarded; 5-year survival maybe ~40-50% with aggressive
therapy. Outcome improves with complete resection and when treated at
experienced centers. TP53 germline CPC has particularly poor outcome due to
inherent resistance.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'><b><span
lang=EN>Note on predisposition:</span></b><span lang=EN> Choroid plexus
carcinoma is a hallmark of Li-Fraumeni syndrome in children (germline TP53)</span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Li,Sarcomas%2C%20adrenocortical%20carcinoma%2C%20breast%20cancer"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'><span
lang=EN>[55]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:choroid-plexus-tumors'><span
lang=EN>, so any CPC, especially bilateral or in an infant, warrants genetic
evaluation.</span></span></span></span></p>

<span style='mso-bookmark:choroid-plexus-tumors'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=embryonal-tumors><span lang=EN>Embryonal
Tumors</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
lang=EN>Embryonal tumors are a group of highly malignant (WHO grade 4) tumors
thought to arise from primitive progenitor cells. They are generally composed
of densely packed small round blue cells. Historically all called PNET, they
are now separated by specific molecular types. Key pediatric embryonal tumors
include: - <b>Medulloblastoma</b>  the most common malignant brain tumor in
children, arising in cerebellum. - <b>Atypical Teratoid/Rhabdoid Tumor (ATRT)</b>
 occurs in infants, defined by loss of INI1 protein (SMARCB1 mutation). - <b>Embryonal
Tumor with Multilayered Rosettes (ETMR)</b>  rare infant tumor, usually with
C19MC alteration. - <b>Other newly defined entities:</b> <b>CNS neuroblastoma,
FOXR2-activated</b> and <b>CNS tumor with BCOR internal tandem duplication</b>
(these cover tumors that were previously CNS-PNET, now recognized by molecular
drivers)</span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Cribriform%20neuroepithelial%20tumor%20,pdf%20page%2012%20of%2021"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
lang=EN>[56]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
lang=EN>. - <b>Pineoblastoma</b>  an embryonal tumor of the pineal (covered in
pineal section). - (Historical note: older terms like CNS PNET, e.g.
ependymoblastoma or medulloepithelioma, have been retired or folded into
ETMR).</span></span></span></span></p>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><a
name=medulloblastoma><span lang=EN>Medulloblastoma</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>Medulloblastoma is a
malignant embryonal tumor of the <b>cerebellum</b> (posterior fossa). It is a
leading cause of cancer mortality in children but also one of the most
treatable CNS tumors with combined modality therapy. Medulloblastomas are all
WHO grade 4 by definition</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=confuse%20clinical%20care%20,current%20therapeutic%20regi%EF%BF%BEmens%20such%20that"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[27]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>, reflecting their
aggressive nature but also highly therapy-responsive in many cases (especially
certain subgroups)</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=confuse%20clinical%20care%20,current%20therapeutic%20regi%EF%BF%BEmens%20such%20that"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[27]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><b><span lang=EN>Epidemiology:</span></b><span
lang=EN> Primarily a pediatric tumor (peak incidence at age 39). It accounts
for ~20% of pediatric brain tumors. Slight male predominance. Rare in adults.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><b><span lang=EN>Location:</span></b><span
lang=EN> Arises in the cerebellum  midline (vermis) in younger children (often
causing truncal ataxia) or cerebellar hemisphere in teens. Often extends into
4th ventricle. CSF dissemination at diagnosis is seen in ~30% cases (drop
metastases to spinal cord or nodules in subarachnoid space).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><b><span lang=EN>Molecular Classification:</span></b><span
lang=EN> A landmark development is the classification into <b>4 major molecular
subgroups</b></span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Medulloblastoma%20has%20been%20classified%20into,metastatic%20and%20have%20the%20best"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[57]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>: 1. <b>WNT-activated</b> 
(~10% of cases). Typically older children (average ~10 years). Often arise from
cerebellar peduncle region. Very good prognosis (5-year OS &gt;90% with
therapy)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Medulloblastoma%20has%20been%20classified%20into,metastatic%20and%20have%20the%20best"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[57]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=%28Table%203%29.%20%287%29%20WNT,metastatic%20and%20have%20the%20best"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[58]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. Characterized by CTNNB1
(-catenin) mutations and often monosomy 6</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%97%8A%20Associated%20with%20colon%20cancer%2C,hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[59]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. <b>Nuclear -catenin IHC
positive</b> in most (a diagnostic clue). Hardly ever metastatic at diagnosis</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=%28Table%203%29.%20%287%29%20WNT,metastatic%20and%20have%20the%20best"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[58]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. 2. <b>SHH-activated</b> 
(~30%). Can occur bimodally: infants and adolescents. Sonic Hedgehog pathway
activated (mutations in PTCH1, SMO, SUFU, or amplifications like GLI2, MYCN).
Prognosis intermediate, but varies: infants without TP53 mutation do well;
older children with TP53 mutant SHH medullo (often associated with Li-Fraumeni)
do poorly</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%28Gorlin%20syndrome%29%20SHH,activated%20medulloblastomas"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[60]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%80%A2%20Most%20common%20in%20children,activated%20medulloblastomas"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[61]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. <b>Gorlin syndrome (PTCH1
germline)</b> predisposes to SHH medulloblastoma</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%28Gorlin%20syndrome%29%20SHH,activated%20medulloblastomas"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[60]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - SHH subgroup can be <b>SHH
TP53-wildtype</b> (average prognosis) or <b>SHH TP53-mutant</b> (very poor,
tends to be in 1017 years old, often Li-Fraumeni)</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%28Gorlin%20syndrome%29%20SHH,activated%20medulloblastomas"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[60]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. 3. <b>Group 3</b> 
(~25%). Non-WNT, non-SHH, historically classic or c-MYC driven. Often
infants or young children, frequently metastatic at diagnosis, often large
cell/anaplastic histology. MYC amplification is common in Group 3, and it
portends a very poor prognosis (5-year OS can be ~50% or less)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Medulloblastoma%20has%20been%20classified%20into,metastatic%20and%20have%20the%20best"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[57]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. Male predominance. 4. <b>Group
4</b>  (~35%). The most common subgroup. Characterized by certain structural
variations (e.g. isochromosome 17q). No single dominant pathway like WNT/SHH.
Intermediate prognosis. Often presents age ~7, more males. Frequently
metastatic but outcome is a bit better than Group 3. Group 4 can have MYCN or
CDK6 amplifications in some cases.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>These molecular subgroups
have <b>prognostic and potential treatment implications</b></span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Medulloblastoma%20is%20divided%20into%204,there%20is%20molecular%20and%20clinical"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[62]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. They are now integrated
into risk stratification along with clinical factors</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=disease%2C%20which%20has%20limited%20treatment,IMAGE%20FOR%20PAGE%3A%2081"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[63]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. For example, WNT is low
risk (excellent prognosis), standard therapy might be de-escalated; Group 3
high MYC is very high risk potentially needing intensification.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><b><span lang=EN>Histological Variants:</span></b><span
lang=EN> - Classic (small round blue cells, Homer Wright rosettes common). -
Desmoplastic/Nodular (with pale islands)  often SHH-subgroup infants. - Large
cell/Anaplastic  aggressive histology, common in Group 3 and SHH TP53-mutant.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><b><span lang=EN>Diagnostic Workup:</span></b><span
lang=EN> MRI of brain and spine pre-op (to assess metastasis)</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=ped_cns%20NCCN%20Guidlines,2025"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[64]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>, and CSF cytology (lumbar
puncture) after surgery (1014 days post-op)</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=NCCN%20Guidelines%20Version%203,For%20medulloblastomas%2C%20the"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[65]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. Staging uses Chang
criteria (M0 = localized, M1 = CSF microscopic, M2/M3 gross nodules, M4
extraneural). Molecular testing (by either IHC, sequencing or DNA methylation)
is now standard to assign subgroup.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><b><span lang=EN>Standard Risk vs High
Risk:</span></b><span lang=EN> Clinically, medulloblastoma patients are
stratified: - <b>Standard/average risk:</b> Age 3, &lt;1.5 cm^2 residual tumor
post-op, and M0 (no metastasis). No high-risk molecular features. - <b>High
risk:</b> Presence of metastatic disease (M1M3), or large residual, or younger
than 3 (though &lt;3 usually separate infant category). TP53-mutant SHH is
considered very high risk by some (in trials they separated it).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><b><span lang=EN>Treatment:</span></b><span
lang=EN> Multimodal: - <b>Surgery:</b> Maximal safe resection is critical. Aim
to remove as much as possible, often achieving &gt;90% removal in many cases</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%80%A2%20Treatment%20for%20medulloblastoma%20includes,for%20histologic%20and%20molecular%20classification"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[66]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. This relieves
hydrocephalus and provides tissue for dx. Sometimes a CSF shunt or ETV is
needed for hydrocephalus</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=collectively%20referred%20to%20as%20%E2%80%9CNon,VP"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[67]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - <b>Radiation:</b> This
is key for patients &gt;3. <b>Craniospinal Irradiation (CSI)</b> is given to
eradicate microscopic CSF disease. Standard-risk kids get <b>23.4 Gy CSI</b>
(lower dose) and high-risk get <b>36.0 Gy CSI</b></span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%17CSI%2023,8%20Gy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[68]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%80%A2%20High%20risk%20and%20very,8%20Gy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[69]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. All receive a <b>boost</b>
to the posterior fossa or tumor bed (~54 Gy total)</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%17CSI%2023,8%20Gy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[68]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. (Often 23.4 Gy CSI + 30.6
Gy boost = 54 Gy for average risk; 36 Gy CSI + ~18 Gy boost to ~54 Gy for high
risk)</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%17CSI%2023,8%20Gy"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[68]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. Radiation is not used for
infants &lt;3 due to neurotoxicity</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=WNT%2Fnon,age%20per%20the%20treating%20physician%E2%80%99s"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[70]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - <b>Chemotherapy:</b>
Combined with radiation and post-RT. The <b>Packer regimen</b> is classic for
average risk: weekly vincristine during RT, then 6 cycles of CCNU (lomustine),
cisplatin, vincristine</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Infant%20Medulloblastoma%20AR%20%E2%80%A2%20Chemotherapy,%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[71]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. High-risk protocols (COG
ACNS0332) added <b>carboplatin</b> during RT and used higher CSI dose</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Childhood%20Medulloblastoma%20AR%20%E2%80%A2%20Radiation%2Fchemotherapy,%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[72]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. Infant protocols avoid RT
and use intensive chemo  autologous stem cell transplant (e.g. COG P9934, or
Head Start III which includes high-dose methotrexate, etc.). In the Canadian
consensus, recommendations were: - Average-risk (&gt;3 years, non-metastatic):
CSI 23.4 Gy + boost, with concurrent vincristine, then <b>adjuvant cisplatin,
CCNU, vincristine</b> as per COG ACNS0331</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Infant%20Medulloblastoma%20AR%20%E2%80%A2%20Chemotherapy,%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[71]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - High-risk (metastatic or
residual): CSI 36 Gy + boost, with concurrent vincristine (carboplatin) and
intensive adjuvant chemo as per ACNS0332 Regimen A</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Childhood%20Medulloblastoma%20AR%20%E2%80%A2%20Radiation%2Fchemotherapy,%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[72]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - Infants (&lt;3):
intensive chemotherapy (like CCG 99703 regimen) often with intrathecal chemo if
high-risk features</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=High%20Grade%20Glioma%20%E2%80%A2%20Chemotherapy%2Fradiation,%2B%2F%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[73]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. Some use high-dose chemo
with stem cell rescue (Head Start or other) to avoid radiation</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=WNT%2Fnon,age%20per%20the%20treating%20physician%E2%80%99s"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[70]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - <b>Molecular-targeted
therapy:</b> Not yet standard, but smoothened (SMO) inhibitors (vismodegib)
were tried in SHH-subgroup trials (with limited success in upfront setting).
Ongoing studies will incorporate subgroup stratification (e.g. de-escalating
WNT: possibly omitting chemo or reducing CSI; escalating therapy for Group3). -
<b>Supportive:</b> Endocrine follow-up (growth hormone, thyroid, etc.) since
CSI causes hormonal deficits</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=intermediate%20risk%20for%20medulloblastoma,years%2C%20then%20as%20clinically%20indicated"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[74]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. Neurocognitive rehab for
learning issues.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><b><span lang=EN>Prognosis:</span></b><span
lang=EN> - Average-risk medulloblastoma has ~7585% 5-year survival with
current therapy</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=or%20nodular%20desmoplastic,Recent%20trials"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[75]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. WNT-subgroup is ~95%
survival (some consider it cured in most cases)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Medulloblastoma%20has%20been%20classified%20into,metastatic%20and%20have%20the%20best"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[57]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - High-risk (metastatic)
historically ~5060% 5-year survival. Group 3 with MYC amplification is
&lt;50%. - Infants without RT: outcomes vary by biology; some cured with chemo
alone, but many relapse. - Late effects are significant (neurocognitive decline,
endocrinopathies, risk of strokes from RT, secondary malignancies, hearing loss
from cisplatin, etc.).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><b><span lang=EN>Predisposition:</span></b><span
lang=EN> - <b>Gorlin syndrome</b> (PTCH1 mutation) predisposes to SHH
medulloblastoma</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%17Gorlin%20syndrome%20,Germline%20PTCH1%20and%20SUFU%20mutations"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[76]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2%3B,CREBBP%2C%20and%20EP300%20can%20also"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[77]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - <b>Turcot syndrome type
2</b> (APC gene in FAP) predisposes to medulloblastoma (often WNT subtype)</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%97%8A%20Associated%20with%20colon%20cancer%2C,hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[59]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - <b>Li-Fraumeni</b>
(TP53)  predisposes to SHH medulloblastomas in childhood; these patients
(SHH+TP53 mutant) have particularly poor outcomes</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%80%A2%20Most%20common%20in%20children,activated%20medulloblastomas"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[61]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - <b>BRCA2/Fanconi anemia</b>
biallelic mutations can also lead to medulloblastoma</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2%3B,CREBBP%2C%20and%20EP300%20can%20also"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[78]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>. - <b>PALB2, GPR161, etc.:</b>
recent research shows several other germline mutations in a proportion of
medulloblastomas</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2%3B,CREBBP%2C%20and%20EP300%20can%20also"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>[78]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:medulloblastoma'><span lang=EN>.</span></span></span></span></span></p>

<span style='mso-bookmark:medulloblastoma'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><a
name=atypical-teratoidrhabdoid-tumor-atrt><span lang=EN>Atypical
Teratoid/Rhabdoid Tumor (ATRT)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>ATRT is
a highly malignant embryonal tumor usually occurring in <b>infants and young
toddlers</b>. It can arise anywhere in CNS (posterior fossa is common, also
supratentorial). ATRT is characterized by <b>inactivation of the SMARCB1 (INI1)
gene</b> (or rarely SMARCA4)</span></span></span></span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=ATRT%20tumors%20are%20characterized%20by,there%20is%20global%20loss%20of"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>[79]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>. This
genetic hallmark distinguishes it.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> As the name suggests, it is atypical and heterogeneous (teratoid 
mixed elements, rhabdoid  cells with eccentric nuclei and eosinophilic
cytoplasm). Typically one sees rhabdoid cells (resembling rhabdomyoblasts) and
a mix of primitive neuroepithelial and epithelial-looking areas. Can resemble
medulloblastoma or PNET but with rhabdoid cells.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Loss of <b>SMARCB1 (INI1)</b> on chromosome 22q is seen in ~95%</span></span></span></span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=ATRT%20tumors%20are%20characterized%20by,there%20is%20global%20loss%20of"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>[79]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>. The
remaining ~5% have loss of SMARCA4 (BRG1) instead. SMARCB1 is a tumor
suppressor part of SWI/SNF chromatin remodeling complex. It can be germline
mutated in <b>Rhabdoid Tumor Predisposition Syndrome</b> (some ATRT patients
have a congenital mutation)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Histologically%2C%20the%20loss%20of%20INI1%2C,to%20the%20development%20of%20malignant"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>[80]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN> <b>INI1
protein is absent</b> in tumor nuclei (diagnostic)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Histologically%2C%20the%20loss%20of%20INI1%2C,to%20the%20development%20of%20malignant"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>[80]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>. This
is a critical diagnostic test (INI1-negative by IHC, whereas other embryonal
tumors retain INI1). Other markers: epithelial membrane antigen (EMA) often
positive, GFAP in some cells, neuronal markers in some  reflecting mixed
lineage.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Classification:</span></b><span
lang=EN> There are molecular subgroups of ATRT (TYR, SHH, and MYC groups)
identified by DNA methylation, which may have prognostic differences, but
treatment is not yet subgroup-specific.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical:</span></b><span
lang=EN> Rapidly growing tumor in infants; often presents with signs of
increased ICP. Can disseminate via CSF early.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Due to patient age (usually &lt;3), therapy avoids upfront radiation.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Surgery:</span></b><span
lang=EN> Attempt maximal resection; often difficult if large or invasive.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Chemotherapy:</span></b><span
lang=EN> Very intensive regimens are used. Common approach is <b>high-dose
chemotherapy with stem cell rescue</b>. For example, the European Rhabdoid
Tumor Protocol and COG protocol ACNS0333 use multi-agent induction
(vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate in
some) followed by high-dose thiotepa or carboplatin-based chemo with autologous
stem cell transplant</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Maximal%20safe%20surgical,CCG%2099703"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>[81]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Intrathecal chemo:</span></b><span
lang=EN> Sometimes given (e.g. methotrexate, cytarabine) due to high risk of
leptomeningeal spread</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=VCR%2FCarboplatin%20,19"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>[82]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Radiation:</span></b><span
lang=EN> Often <b>avoided or delayed</b> until child is older because infants
suffer severe side effects. If tumor persists or recurs and child &gt;3, focal
RT (or even CSI if disseminated) might be done. Some centers do focal RT in
children as young as 1 if needed (proton therapy can be considered).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>The Canadian consensus: ATRT
therapy is chemo per 99703 (infant brain tumor regimen) +/ maintenance chemo,
avoid/delay RT</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Ependymoma%20Localized%20%E2%80%A2%20Focal%20radiation,%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>[83]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> ATRT is among the poorest of pediatric brain tumors. Median survival
~1218 months in many series. Some improvement seen with aggressive regimens:
2-year survival up to ~3040% in recent reports with high-dose chemo. Long-term
survivors exist (especially if complete remission achieved and possibly with
some radiation or focal therapy).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo29'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Predisposition:</span></b><span
lang=EN> ~30% of ATRT patients have a germline SMARCB1 mutation (Rhabdoid
predisposition syndrome)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Histologically%2C%20the%20loss%20of%20INI1%2C,to%20the%20development%20of%20malignant"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>[80]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'><span lang=EN>, which
also causes rhabdoid tumors in kidney or soft tissue. These families need
genetic counseling and screening of siblings.</span></span></span></span></span></p>

<span style='mso-bookmark:atypical-teratoidrhabdoid-tumor-atrt'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><a
name=X76e2627d5aa903eb49c0db0208e307ddb4e3ca8><span lang=EN>Embryonal Tumor
with Multilayered Rosettes (ETMR)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'><span lang=EN>ETMR
is a rare, highly aggressive embryonal tumor typically in infants. It was
defined in WHO 2016/2021 as combining entities like ependymoblastoma and
medulloepithelioma. A hallmark is <b>C19MC locus alteration</b> (a microRNA
cluster amplification) on chromosome 19.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo30'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> Small round blue cell tumor with ependymoblastic rosettes (true
multilayered rosettes reminiscent of embryonic neural tube). Also areas of
neuroepithelial tube-like structures. It may have divergent differentiation.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo30'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> ~90% have <b>C19MC amplification</b> (fusion of TTYH1 with C19MC
region). If C19MC amp is absent, some still classify as ETMR if they have
classic histology and LIN28A expression. <b>LIN28A</b> IHC is strongly positive
in most ETMR and is a useful diagnostic marker</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Supratentorial%20ependymoma%2C%20ZFTA%20fusion,to%20allow%20for%20genetic%20subtypes"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'><span lang=EN>[84]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo30'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>IHC:</span></b><span lang=EN>
LIN28A positive (helps distinguish from medullo). INI1 is retained (helps vs
ATRT).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo30'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Location:</span></b><span
lang=EN> Often supratentorial (cerebrum) in infants, but can be anywhere
including brainstem.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo30'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> No standardized regimen due to rarity, but generally maximal surgery
and intensive chemo similar to other infant malignancies. Some have attempted
approaches like those for ATRT or using the Head Start protocol. Radiation is
usually not feasible due to infant age. Outcome is extremely poor.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo30'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Median survival &lt;12 months in many cases. Very few long-term
survivors reported.</span></span></span></span></span></p>

<span style='mso-bookmark:X76e2627d5aa903eb49c0db0208e307ddb4e3ca8'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><a
name=cns-neuroblastoma-foxr2-activated><span lang=EN>CNS Neuroblastoma,
FOXR2-activated</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:cns-neuroblastoma-foxr2-activated'><span lang=EN>This is a
new entity encompassing some tumors that were previously CNS embryonal tumor
NOS which have a specific genetic driver: activation of FOXR2 (often by gene
fusion).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo31'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:cns-neuroblastoma-foxr2-activated'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical/Pathology:</span></b><span
lang=EN> Occur in children, often cerebral hemispheres. Histology resembles
other small round cell tumors (neuroblastoma-like or CIC-rearranged tumor-like)
 small blue cells, maybe some neuropil-like areas.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo31'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:cns-neuroblastoma-foxr2-activated'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> <b>FOXR2</b> overexpression (via fusion with another gene, or other
enhancer hijacking) is the defining feature (detected by DNA methylation
profiling typically).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo31'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:cns-neuroblastoma-foxr2-activated'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Given embryonal nature, would be treated like a high-risk PNET:
surgery, craniospinal RT (if age allows), intensive chemo. But exact protocols
arent established (some might follow medullo or ETMR-like regimens).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo31'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:cns-neuroblastoma-foxr2-activated'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Not well-defined yet; likely poor if high-grade.</span></span></span></span></span></p>

<span style='mso-bookmark:cns-neuroblastoma-foxr2-activated'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><a
name=X57f64594ef069ce1e6d6f57529d6c5d8229acdd><span lang=EN>CNS Tumor with BCOR
Internal Tandem Duplication</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X57f64594ef069ce1e6d6f57529d6c5d8229acdd'><span lang=EN>Another
new molecularly-defined tumor (previously some CNS PNET fell here).
Characterized by an <b>internal tandem duplication in the BCOR gene</b>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo32'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X57f64594ef069ce1e6d6f57529d6c5d8229acdd'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical:</span></b><span
lang=EN> Typically seen in young children, often supratentorial.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo32'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X57f64594ef069ce1e6d6f57529d6c5d8229acdd'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> High-grade round cell tumor, can have some faint resemblance to
embryonal tumor or sarcoma.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo32'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X57f64594ef069ce1e6d6f57529d6c5d8229acdd'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> BCOR ITD is identified via sequencing or methylation profile.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo32'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:X57f64594ef069ce1e6d6f57529d6c5d8229acdd'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment/Prognosis:</span></b><span
lang=EN> Also not well established. Analogous tumors outside CNS (e.g. clear
cell sarcoma of kidney with BCOR) are aggressive. In CNS, limited cases but
prognosis appears poor without intensive therapy. Likely treat with surgery +
intensive chemo  RT.</span></span></span></span></span></p>

<span style='mso-bookmark:X57f64594ef069ce1e6d6f57529d6c5d8229acdd'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><a
name=other-rare-embryonal-tumors><span lang=EN>Other Rare Embryonal Tumors</span></a></span></span></span></h3>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo33'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:other-rare-embryonal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>CNS WHO 2021</span></b><span
lang=EN> lists <b>CIC-rearranged sarcoma</b> and <b>intracranial sarcoma,
DICER1-mutant</b> which, while labeled sarcomas, can histologically resemble
embryonal tumors and occur in children (discussed under mesenchymal section).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo33'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:other-rare-embryonal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Medulloepithelioma:</span></b><span
lang=EN> A very rare primitive neuroepithelial tumor (previously separate, now
usually considered under ETMR if multilayered rosettes). Arises in young kids,
e.g. in the cerebrum or even retina (embryonal tumor of ciliary body).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo33'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:other-rare-embryonal-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Pituitary Blastoma:</span></b><span
lang=EN> An extremely rare embryonal tumor of the pituitary in infants,
associated with DICER1 syndrome (see pituitary section).</span></span></span></span></span></p>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:other-rare-embryonal-tumors'><b><span lang=EN>Therapy Note:</span></b><span
lang=EN> Historically, all non-medulloblastoma embryonal tumors in CNS were
treated with PNET protocols similar to high-risk medulloblastoma (CSI +
chemo). Outcomes for these (old CNS PNET category) were generally worse than
medulloblastoma. With new molecular classification, tailored approaches may
emerge (for example, ATRT now has dedicated protocols, ETMR might in future,
etc.). However, whenever possible, aggressive multimodal therapy is used. The <b>Canadian
consensus</b> suggests: - For <b>ATRT</b>: chemo-intensive approach, delay
radiation</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Ependymoma%20Localized%20%E2%80%A2%20Focal%20radiation,%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:other-rare-embryonal-tumors'><span lang=EN>[83]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:other-rare-embryonal-tumors'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:embryonal-tumors'><span
style='mso-bookmark:other-rare-embryonal-tumors'><span lang=EN>. - For <b>pineoblastoma</b>:
often treated like high-risk medulloblastoma with CSI (see pineal tumors). -
For <b>others</b> (FOXR2, BCOR): no specific mention, likely handled
case-by-case.</span></span></span></span></span></p>

<span style='mso-bookmark:other-rare-embryonal-tumors'></span><span
style='mso-bookmark:embryonal-tumors'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=germ-cell-tumors-gcts><span lang=EN>Germ
Cell Tumors (GCTs)</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>Intracranial germ cell tumors typically occur in children and
adolescents, usually in the midline (pineal and suprasellar regions). They are
analogous to gonadal germ cell tumors, with similar histologic subtypes. GCTs
are most common in <b>East Asia</b> (higher incidence in Japan/Korea) but also
occur in Western populations</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=%28112%2C%20114%E2%80%93116%29,in%20the%20serum%20and%20lumbar"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>[85]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>. They constitute about 35% of pediatric CNS tumors in the West</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Tumors%20Introduction%3A%20Primary%20intracranial%20germ,affecting%20both%20the%20pineal%20and"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>[86]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>, and up to 810% in East Asia. Median age ~1012 years; more common in
males, especially pineal tumors (10:1 male/female for pineal germinoma)</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=%28112%2C%20114%E2%80%93116%29,in%20the%20serum%20and%20lumbar"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>[85]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><b><span
lang=EN>Types of CNS GCT:</span></b><span lang=EN> - <b>Germinoma</b> (also
called pure germinoma or dysgerminoma/seminoma equivalent)  by far the most
common (6070% of intracranial GCTs)</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=are%20predominantly%20located%20in%20the,decade%20of%20life%2C%20and%20in"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>[87]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>. - <b>Non-germinomatous germ cell tumors (NGGCT):</b> includes - <b>Teratoma</b>
(mature or immature; mature teratoma is benign), - <b>Yolk sac tumor
(endodermal sinus tumor)</b>, - <b>Choriocarcinoma</b>, - <b>Embryonal
carcinoma</b>, - <b>Mixed GCT</b> (with components of the above). - Also a
special entity: <b>Teratoma with malignant transformation</b> (rare).</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><b><span
lang=EN>Clinical Presentation:</span></b><span lang=EN> - <b>Pineal region
tumors</b> (pineal GCT): present with Parinauds syndrome (upward gaze palsy),
hydrocephalus (headache, vomiting). - <b>Suprasellar GCT</b>: present with
diabetes insipidus, visual field deficits, hormonal deficiencies
(hypopituitarism, delayed puberty). - Some patients have synchronous tumors in
pineal and suprasellar (bifocal GCT) which strongly suggests germinoma</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=%28112%2C%20114%E2%80%93116%29,decade%20of%20life%2C%20and%20in"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>[88]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>. - <b>Tumor markers:</b> These are critical for diagnosis. Germinomas
can secrete low levels of beta-human chorionic gonadotropin (-HCG) (usually
&lt;100 IU/L)</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Asia%20%282%2C%20112%2C%20113%2C%20115%29,113"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>[89]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>; if -HCG is modestly elevated, it can still be pure germinoma</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Asia%20%282%2C%20112%2C%20113%2C%20115%29,113"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>[89]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>. Non-germinomatous components: yolk sac tumors secrete
alpha-fetoprotein (AFP), choriocarcinoma secretes high -HCG (often thousands).
So serum and CSF <b>AFP and -HCG</b> are measured; elevated AFP or high HCG
indicates NGGCT</span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=commonly%20germinomas%20%28113%29,113"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>[90]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>. - <b>Diagnosis:</b> If markers are diagnostic (e.g. clear elevation
of AFP &gt;10 or HCG &gt;100), one may start treatment without biopsy
(especially in midline where biopsy is risky)</span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=for%20receptive%20and%20expressive%20language,The%20standard%20of"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>[91]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
lang=EN>. Otherwise, surgical biopsy or resection is done. Germinomas are soft,
gray, homogenous; teratomas are more heterogeneous with calcifications.</span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><b><span
lang=EN>Treatment and Outcome differ markedly between Germinoma and NGGCT:</span></b></span></span></span></p>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><a
name=germinoma><span lang=EN>Germinoma</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'><span lang=EN>Germinomas are very radiosensitive
and chemo-sensitive, with overall excellent prognosis (survival &gt;90% with
proper therapy). The strategy is to use <b>combination of chemotherapy and
radiotherapy</b> to minimize long-term effects: - <b>Chemotherapy:</b>
Platinum-based chemo (carboplatin or cisplatin + etoposide, sometimes
ifosfamide) is given for 24 cycles. - <b>Radiation:</b> After chemo, a reduced
volume/dose radiation. Standard historically was full dose RT alone: CSI 24 Gy
+ boost to 45 Gy for germinoma, which cured ~90% but caused late effects.
Modern approaches reduce field: - <b>Whole Ventricular Irradiation (WVI)</b> ~
1824 Gy with a boost to tumor bed (total ~3036 Gy). This is for localized
germinoma (pineal or suprasellar). - If multifocal or disseminated, <b>CSI</b>
(2124 Gy) with primary site boost ~boost to 3036 Gy. - Some protocols use **
focal RT only <b>to tumor (~4045 Gy) after chemo in localized cases, but risk
of marginal relapse is higher, so WVI is more common now in NA. - In the</b>
ACNS1123 trial <b>(COG), localized germinoma got chemo (carbo/etoposide) then
18 Gy WVI + 12 Gy boost (30 Gy total)</b></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=ATRT%20%E2%80%A2%20Chemotherapy%20per%2099703,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'><b><span lang=EN>[92]</span></b></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'><b><span lang=EN>. Disseminated got 24 Gy CSI +
boost</span></b></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=radiation%20Germinoma%20Localized%20%E2%80%A2%20Chemotherapy,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'><b><span lang=EN>[93]</span></b></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'><b><span lang=EN>. -</span></b><span lang=EN>
Surgery: <b>Typically just biopsy. Resection not needed for germinoma because
it responds well to chemoRT and surgery has high morbidity in those locations.
-</b> Outcome:** ~90% event-free survival. Relapses can often be salvaged with
additional RT or chemo + stem cell transplant.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'><b><span lang=EN>Canadian consensus:</span></b><span
lang=EN> for <b>Localized Germinoma</b>, chemo per ACNS1123 (carboplatin/etop)
with <b>WVI  boost</b></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=ATRT%20%E2%80%A2%20Chemotherapy%20per%2099703,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'><span lang=EN>[94]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'><span lang=EN>; for <b>Disseminated Germinoma</b>,
same chemo with CSI added</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=radiation%20Germinoma%20Localized%20%E2%80%A2%20Chemotherapy,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'><span lang=EN>[95]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:germinoma'><span lang=EN>.</span></span></span></span></span></p>

<span style='mso-bookmark:germinoma'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><a
name=non-germinomatous-gct-nggct><span lang=EN>Non-Germinomatous GCT (NGGCT)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'><span lang=EN>These are more
aggressive and require intensive therapy. Treatment: - <b>Chemotherapy:</b> 46
cycles of a intensive regimen. Commonly used is <b>PEI</b> (cisplatin,
etoposide, ifosfamide)  this is the backbone of the <b>SIOP CNS GCT96</b>
trial regimen</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20SIOP%20CNS%20GCT,with%20CSI%20for%20all%20patients"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'><span lang=EN>[96]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'><span lang=EN>. COGs regimen <b>ACNS0122</b>
used carboplatin, etoposide, and ifosfamide with cycles alternating with
cyclophosphamide/vincristine, followed by high-dose chemo with stem cell
rescue. Markers often drop to normal if chemo is effective. - <b>Second-look
surgery:</b> Often after chemo, if residual tumor on MRI, surgical resection is
attempted especially if its a teratoma component (since mature teratoma
doesnt respond to chemo/RT). This is debated, but many centers do resect
residual masses. - <b>Radiation:</b> Crucial for cure. Because NGGCT have high
risk of microscopic spread, <b>CSI</b> is typically given: - Localized (no
metastasis on imaging/CSF): CSI ~30 Gy, plus primary tumor boost to ~54 Gy. -
Metastatic: CSI ~36 Gy, plus boosts to primary and large metastases. - <i>Some
European protocols (SIOP) if markers normalize and complete response achieved,
use only focal RT, but North American standard is CSI for all NGGCT due to
relapse risk.</i></span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20SIOP%20CNS%20GCT,with%20CSI%20for%20all%20patients"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'><span lang=EN>[96]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'><span lang=EN>. - <b>Outcome:</b>
NGGCT 5-year survival is ~70% in recent series. Its worse if there is
choriocarcinoma or high HCG burden. Relapses often involve spine or CNS
dissemination if not handled initially. - <b>Consensus practice:</b> Canadian
centers use either SIOP or COG regimen; Table shows either <b>SIOP CNS GCT-96</b>
or <b>ACNS0122</b>, with <b>localized NGGCT</b>: chemo then tumor bed RT</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Germinoma%20Localized%20%E2%80%A2%20Chemotherapy%20per,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'><span lang=EN>[97]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'><span lang=EN>, <b>disseminated
NGGCT</b>: chemo then CSI</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=tumor%20Disseminated%20%E2%80%A2%20Chemotherapy%20per,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'><span lang=EN>[98]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'><span lang=EN>. - <b>Follow-up:</b>
Both germinoma and NGGCT need long-term endocrine and neuropsych follow-up.
Hormone replacement is often needed (DI, sex hormones, thyroid, GH) especially
for suprasellar tumor survivors.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:germ-cell-tumors-gcts'><span
style='mso-bookmark:non-germinomatous-gct-nggct'><b><span lang=EN>Special
notes:</span></b><span lang=EN> - <b>Teratomas:</b> Mature teratoma is treated
with surgery alone (curative if totally removed). Immature teratomas might get
chemo if malignant elements present. They do not need RT if no malignant
component. - <b>Diagnosis nuance:</b> Sometimes biopsy of a germ cell tumor
shows only germinoma but markers suggest NGGCT (i.e., an unseen yolk sac
component). In such cases, treat as NGGCT (higher intensity), because treating
as germinoma would under-treat the malignant component. Thus, therapy is guided
by <b>highest malignancy component</b>. - <b>Bifocal germinoma:</b> If DI +
pineal mass, often germinoma  these can be treated with cranial irradiation
(covering both sites) and chemo, sometimes avoiding CSI since they are only
intracranial, not spinal (some treat whole ventricles and both tumor sites).</span></span></span></span></span></p>

<span style='mso-bookmark:non-germinomatous-gct-nggct'></span><span
style='mso-bookmark:germ-cell-tumors-gcts'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=sellar-region-tumors><span lang=EN>Sellar
Region Tumors</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
lang=EN>Tumors in the hypothalamic-pituitary region of children include <b>craniopharyngiomas</b>
and less commonly <b>pituitary adenomas</b> (and extremely rare <b>pituitary
blastomas</b> in infants).</span></span></span></span></p>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><a
name=craniopharyngioma><span lang=EN>Craniopharyngioma</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>Craniopharyngiomas (CP)
are benign epithelial tumors arising from remnants of Rathkes pouch (embryonic
pituitary precursor) in the suprasellar region. They account for ~510% of
pediatric brain tumors</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Craniopharyngioma%20Introduction%3A%20Craniopharyngiomas%20,of%20the%20most%20frequently%20diagnosed"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[99]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. Two histologic subtypes:
- <b>Adamantinomatous craniopharyngioma (adamantinomatous CP)</b>  occurs in
children; has wet keratin, machine oil cysts, calcifications. Driven by <b>CTNNB1
(-catenin) mutations</b> leading to Wnt activation</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=100%29,101"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[100]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. - <b>Papillary
craniopharyngioma</b>  occurs in adults; has BRAF V600E mutations</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=are%20predominantly%20diagnosed%20with%20the,101"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[101]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN> (rare in children).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>Children almost
exclusively get the adamantinomatous type</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=100%29,101"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[100]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><b><span lang=EN>Clinical:</span></b><span
lang=EN> Presents with symptoms of: - Increased intracranial pressure
(headache, vomiting) from hydrocephalus. - Visual disturbances (classically
bitemporal hemianopsia) from optic chiasm compression</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=proximity%20to%20critical%20structures%20surrounding,whereas%20adults%20typically"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[102]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. - Endocrine dysfunction
(growth failure, diabetes insipidus, pituitary hormone deficits) from
pituitary/hypothalamic compression</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=adenohypophysis%20%2896%29,predominantly%20diagnosed%20with%20the%20adamantinomatous"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[103]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. - Often a mix of these.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><b><span lang=EN>Radiology:</span></b><span
lang=EN> Typically a mixed solid-cystic suprasellar mass with calcifications
(which are very common and a clue). Cyst fluid is often cholesterol-rich (motor
oil appearance on aspiration).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><b><span lang=EN>Behavior:</span></b><span
lang=EN> Benign (WHO grade 1) histologically, but can be locally aggressive due
to location near critical structures (visual pathways, hypothalamus)</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=adenohypophysis%20%2896%29,predominantly%20diagnosed%20with%20the%20adamantinomatous"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[103]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. Tends to adhere to
surrounding brain, making complete resection difficult and risky. Local
recurrences are common (even years later) if not completely resected or
adequately irradiated.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><b><span lang=EN>Treatment Approaches:</span></b><span
lang=EN> - <b>Surgery:</b> Traditional approach has been attempt at gross total
resection (often via craniotomy or transsphenoidal if primarily in sella).
While complete resection can cure, it carries significant morbidity
(hypothalamic obesity, panhypopituitarism, cognitive issues)</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=mutations%20%28101%29,There%20are"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[104]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. Modern strategy often
favors a more conservative resection to avoid hypothalamic injury, followed by
targeted therapy to residual (radiation or intracystic). - <b>Radiation:</b>
Very effective in controlling residual craniopharyngioma. <b>Conformal
fractionated radiation (~54 Gy)</b> is standard for residual tumor or
recurrence</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20,20"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[105]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. Proton therapy is often
used to spare normal tissue. In older children and adults, often a subtotal
resection followed by radiotherapy yields equivalent tumor control to gross
total resection but with fewer complications. - <b>Intracystic therapies:</b>
Particularly for predominantly cystic tumors, <b>intracystic interferon-2b</b>
or <b>intracystic bleomycin</b> can be used. The Canadian survey noted that
many centers use <b>intracystic interferon alpha</b> as first-line in young
children with cystic craniopharyngiomas to delay or avoid radical surgery/RT</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=beneficial%20%28102%29,need%20for%20surgery%20and%20radiation"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[106]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=institutions%20have%20been%20using%20intracystic,comes%20from%20the%20premise%20that"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[107]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. Interferon is instilled
via an Ommaya reservoir; it can shrink cysts in ~70% of patients and buy time</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=amendable%20to%20the%20safe%20endoscopic,recognized%20to%20have%20anti%EF%BF%BEproliferative%20and"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[108]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=demonstrate%20in%20their%20respective%20cohorts,recognized%20to%20have%20anti%EF%BF%BEproliferative%20and"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[109]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. It is relatively
low-toxicity (flu-like side effects)</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=carcinomas%20where%20this%20agent%20is,two%20approaches%20are%20summarized%20below"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[110]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. - In the consensus, 8 of
16 Canadian centers use IFN intracystically for cystic cases</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=intracystic%20catheters%20and%20IFN%20instillation,Treatment%20Plan"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[111]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. Regimen example: IFN 3
million IU injected M/W/F for 4 weeks as one cycle</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20,Central%20Nervous%20System%20Germ%20Cell"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[112]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. - <b>Chemotherapy:</b>
There are <b>no effective systemic chemotherapies</b> for craniopharyngioma</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=treatment%20is%20safe%20surgical%20resection%3B,102"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[113]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. Targeted therapy with
BRAF inhibitors is an option for the rare pediatric papillary type (BRAF^V600E)
 some adult case reports of BRAF inhibitor causing tumor shrinkage. - <b>Optimal
strategy:</b> Many advocate limited surgery (like cyst decompression or partial
removal to relieve pressure) plus radiation for tumor control, rather than
radical resection, to preserve hypothalamic function</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=mutations%20%28101%29,There%20are"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[104]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. Hypothalamic obesity and
cognitive impairment are major concerns if the hypothalamus is damaged</span></span></span></span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=a%20complete%20resection,safe%20endoscopic%20insertion%20of%20indwelling"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>[114]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:craniopharyngioma'><span lang=EN>. - <b>Endocrine
management:</b> Almost all patients require lifelong hormone replacement
(growth hormone, thyroid, adrenal, sex steroids, DDAVP for DI). - <b>Prognosis:</b>
5-year survival ~90% (most patients die with disease not from it). However,
quality of life can be severely affected by obesity, vision loss, etc.
Recurrence is common (up to 50% at 10 years if no radiation). Surveillance MRIs
are needed long-term.</span></span></span></span></span></p>

<span style='mso-bookmark:craniopharyngioma'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><a
name=Xb993388c579b7a3eeea6f0d1538c47524545021><span lang=EN>Pituitary Adenomas
and Pituitary Blastoma</span></a></span></span></span></h3>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo34'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:Xb993388c579b7a3eeea6f0d1538c47524545021'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Pituitary Adenomas:</span></b><span
lang=EN> Rare in pre-pubertal children, but can occur in adolescence. Most
often functional (e.g. Cushing disease from ACTH adenoma, or prolactinoma).
They are WHO grade 1 benign neoplasms of pituitary gland. In pediatric
patients, <b>prolactinomas</b> are actually relatively more common (especially
in teenage girls or boys with macroadenomas). Treatment is usually medical for
prolactinomas (dopamine agonists like cabergoline). ACTH adenomas causing
Cushings require transsphenoidal surgery. Growth hormone secreting adenomas
(acromegaly) are extremely rare in childhood (gigantism).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo34'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:Xb993388c579b7a3eeea6f0d1538c47524545021'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Pituitary adenomas can be part of <b>MEN1
syndrome</b> (rare in pediatrics).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo34'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:Xb993388c579b7a3eeea6f0d1538c47524545021'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Transsphenoidal surgery for non-prolactinoma adenomas. Medical therapy
for prolactinomas. Radiotherapy only if persistent or recurrent unresectable
tumors.</span></span></span></span></span></p>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='mso-list:l1 level1 lfo34'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:sellar-region-tumors'><span style='mso-bookmark:Xb993388c579b7a3eeea6f0d1538c47524545021'><b><span
     lang=EN>Prognosis:</span></b><span lang=EN> Excellent in terms of tumor
     control, but hormone deficits can result either from tumor or treatment.</span></span></span></span></span></li>
 <li class=MsoNormal style='mso-list:l1 level1 lfo34'><span style='mso-bookmark:
     Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span style='mso-bookmark:content'><span
     style='mso-bookmark:sellar-region-tumors'><span style='mso-bookmark:Xb993388c579b7a3eeea6f0d1538c47524545021'><b><span
     lang=EN>Pituitary Blastoma:</span></b><span lang=EN> An extremely rare
     embryonal tumor of the pituitary in infants (usually &lt;1 year). It
     arises in context of <b>DICER1 syndrome</b> often (so if diagnosed, test
     for DICER1 germline). Presents with Cushing syndrome in an infant (due to
     ACTH production) and a sellar mass.</span></span></span></span></span></li>
</ul>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo34'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:Xb993388c579b7a3eeea6f0d1538c47524545021'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Surgery (often subtotal) plus maybe chemo has been attempted, and
occasionally radiation if child is old enough. Some cases have poor outcome,
but a few survived with multimodal therapy.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo34'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:sellar-region-tumors'><span
style='mso-bookmark:Xb993388c579b7a3eeea6f0d1538c47524545021'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Because of rarity, its included
here only for completeness. Its essentially the only truly malignant
pituitary-region tumor aside from metastases.</span></span></span></span></span></p>

<span style='mso-bookmark:Xb993388c579b7a3eeea6f0d1538c47524545021'></span><span
style='mso-bookmark:sellar-region-tumors'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=pineal-region-tumors><span lang=EN>Pineal
Region Tumors</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
lang=EN>The pineal gland (epithalamus) is location for various tumor types in
children: - <b>Pineal Parenchymal Tumors:</b> pineoblastoma, pineal parenchymal
tumor of intermediate differentiation (PPTID), pineocytoma. - <b>Germ cell
tumors:</b> (already covered)  pineal is the most common site for germinoma
and NGGCT. - Others: <b>Papillary tumor of pineal region (PTPR)</b>  rare,
young adults; <b>Metastatic tumors</b> (rare in kids).</span></span></span></span></p>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><a
name=pineoblastoma><span lang=EN>Pineoblastoma</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><span lang=EN>Pineoblastoma is a primitive
embryonal tumor of the pineal gland, considered a type of embryonal tumor (WHO
grade 4), sometimes grouped with supratentorial embryonal tumors. It often
occurs in infants and young children (under 5, but also up to preteens). It is
part of trilateral retinoblastoma when associated with germline RB1 mutation
(bilateral retinoblastoma + pineoblastoma).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo35'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Histology:</span></b><span
lang=EN> Small round blue cell tumor, very similar to medulloblastoma or other
PNET. Flexner-Wintersteiner rosettes may be present (like retinoblastoma).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo35'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> No specific defining mutation like medullos WNT/SHH; however,
pineoblastomas are strongly associated with <b>RB1 germline</b> (in patients
with heritable retinoblastoma) and with <b>DICER1 syndrome</b> (pineoblastoma
can occur in DICER1 patients, who also can get pituitary blastoma and other
tumors  collectively pinealoblastoma, pituitary blastoma and DICER1 have an
association known as DICER1 syndrome)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=match%20at%20L855%20GPC3%2C%20GPC4,Wilms%20tumor%2C%20hepatoblastoma%2C%20neuroblastoma%2C%20gonadoblastoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><span lang=EN>[115]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><span lang=EN>.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo35'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Clinical:</span></b><span
lang=EN> Presents with increased ICP (hydrocephalus) and Parinauds syndrome.
Often disseminated at diagnosis (M1 or M2).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo35'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Aggressive, similar to high-risk medulloblastoma:</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo35'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Maximal surgical resection if
possible (though pineal region surgery is high risk).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo35'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>CSI (typically 36 Gy) + boost to
pineal region (~54 Gy) for children &gt;3.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo35'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Multi-agent chemotherapy like
medulloblastoma.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo35'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>In infants: use intensive
chemotherapy with stem cell rescue (Head Start or COG ACNS0334 regimen) because
RT is deferred.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo35'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Outcome:</span></b><span
lang=EN> Historically poor  5-year survival often &lt;50%. But with modern
therapy, some improvement. Trilateral RB (with RB1 mutation) has very poor
prognosis (most die within 2 years).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo35'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:pineoblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Because of high risk, some treat
like NGGCT if markers are negative. In the Canadian consensus, pineoblastoma
wasnt separately listed, but would likely follow medulloblastoma high-risk
style therapy (some protocols combine pineoblastoma with high-risk PNET
regimens).</span></span></span></span></span></p>

<span style='mso-bookmark:pineoblastoma'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><a
name=X7c9dfed97e87572faf2f2ad74219134582713cf><span lang=EN>Pineal Parenchymal
Tumors (PPTs: PPTID &amp; Pineocytoma)</span></a></span></span></span></h3>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo36'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:X7c9dfed97e87572faf2f2ad74219134582713cf'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Pineocytoma:</span></b><span
lang=EN> A well-differentiated pineal tumor (WHO grade 1) occurring in adults
mostly. Rare in children. Composed of mature pinealocytes with neuronal
differentiation. Slow growing. Treated with surgery; excellent prognosis.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo36'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:X7c9dfed97e87572faf2f2ad74219134582713cf'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Pineal Parenchymal Tumor of
Intermediate Differentiation (PPTID):</span></b><span lang=EN> WHO grade 2 or
3, intermediate between pineocytoma and pineoblastoma. Occur in young adults
and sometimes adolescents. More cellular and atypical than pineocytoma, but not
as primitive as pineoblastoma.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo36'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:X7c9dfed97e87572faf2f2ad74219134582713cf'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Often surgery + focal radiation (around 5054 Gy). Sometimes also
chemo. Outcome variable, but generally better than pineoblastoma.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo36'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:X7c9dfed97e87572faf2f2ad74219134582713cf'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>These are rare in pediatric cases.
If encountered, therapy is tailored to grade and behavior.</span></span></span></span></span></p>

<span style='mso-bookmark:X7c9dfed97e87572faf2f2ad74219134582713cf'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><a
name=Xfa89c58bc33df0dbfcdd27dc2d939d847dea04d><span lang=EN>Papillary Tumor of
the Pineal Region (PTPR)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:Xfa89c58bc33df0dbfcdd27dc2d939d847dea04d'><span lang=EN>A
distinct tumor (WHO grade 2 or 3) thought to arise from specialized ependymal
cells of pineal region (the subcommissural organ). Typically in young adulthood
(mean ~30), but can happen in older children.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo37'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:Xfa89c58bc33df0dbfcdd27dc2d939d847dea04d'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Pathology:</span></b><span
lang=EN> Papillary and epithelioid morphology, mucus production. Immuno:
cytokeratins, transthyretin often positive.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo37'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:Xfa89c58bc33df0dbfcdd27dc2d939d847dea04d'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Surgery + radiotherapy. Chemo role unclear. Tends to have chronic
recurrence pattern.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo37'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:Xfa89c58bc33df0dbfcdd27dc2d939d847dea04d'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Rare in kids, mentioned for
completeness.</span></span></span></span></span></p>

<span style='mso-bookmark:Xfa89c58bc33df0dbfcdd27dc2d939d847dea04d'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><a
name=X62e75e83306ba11770820288fd1cf434176ef9a><span lang=EN>Desmoplastic Myxoid
Tumor of Pineal Region, SMARCB1-mutant</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:X62e75e83306ba11770820288fd1cf434176ef9a'><span lang=EN>A
newly recognized entity (WHO 2021) in pineal region that is <b>SMARCB1-mutant</b>,
but unlike ATRT its a distinct desmoplastic myxoid tumor (also called pineal
region rhabdoid tumor in literature). Seems to occur in young patients.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo38'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:X62e75e83306ba11770820288fd1cf434176ef9a'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Path:</span></b><span lang=EN> Desmoplastic
stroma and myxoid change, with some rhabdoid cells. Loss of INI1 by IHC (since
SMARCB1 mutated).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo38'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:X62e75e83306ba11770820288fd1cf434176ef9a'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Behavior:</span></b><span
lang=EN> Unclear, possibly somewhat less aggressive than ATRT (since distinct
name given). But likely malignant.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo38'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:X62e75e83306ba11770820288fd1cf434176ef9a'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treat:</span></b><span lang=EN>
would likely treat similar to ATRT (SMARCB1 loss triggers ATRT-like therapy).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo38'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:pineal-region-tumors'><span
style='mso-bookmark:X62e75e83306ba11770820288fd1cf434176ef9a'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>This entity demonstrates that not
all INI1-negative CNS tumors are classic ATRTs; location and histology matter.</span></span></span></span></span></p>

<span style='mso-bookmark:X62e75e83306ba11770820288fd1cf434176ef9a'></span><span
style='mso-bookmark:pineal-region-tumors'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=meningeal-and-mesenchymal-tumors><span
lang=EN>Meningeal and Mesenchymal Tumors</span></a></span></span></h2>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><a
name=pediatric-meningiomas><span lang=EN>Pediatric Meningiomas</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'><i><span lang=EN>Meningiomas</span></i><span
lang=EN> are tumors of the meninges (coverings of brain). They are usually
benign (grade 1) in adults. In children, meningiomas are rare but do occur,
often in special contexts: - <b>Neurofibromatosis type 2 (NF2)</b>: causes
multiple meningiomas from teens onward</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=NF2%20Schwannoma%2C%20meningioma%2C%20astrocytoma%2C%20ependymoma,Malignant%20peripheral%20nerve"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'><span lang=EN>[116]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'><span lang=EN>. - History of cranial
irradiation: childhood cancer survivors (e.g. leukemia CNS prophylaxis) can get
radiation-induced meningiomas a decade later. - Some sporadic meningiomas
happen, sometimes atypical or clear-cell variants, even in very young kids.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'><b><span lang=EN>Features:</span></b><span
lang=EN> Meningiomas in children more often have atypical histology and are
more often located in unusual places (intraventricular, etc.) and a higher male
ratio than in adults.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'><b><span lang=EN>Pathology:</span></b><span
lang=EN> Same as adult types (whorls, psammomas for grade 1; increased mitoses
for grade 2 atypical; anaplastic features for grade 3). NF2-related meningiomas
often have loss of NF2 gene (merlin)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=NF2%20Schwannoma%2C%20meningioma%2C%20astrocytoma%2C%20ependymoma,Malignant%20peripheral%20nerve"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'><span lang=EN>[116]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'><b><span lang=EN>Treatment:</span></b><span
lang=EN> - <b>Surgery</b> is primary; many pediatric meningiomas can be cured
if totally resected (Simpson I). - <b>Radiation:</b> reserved for subtotally
resected or higher grade meningiomas. In NF2 patients, often multiple
meningiomas  radiosurgery is used for small ones, or watch-and-wait if
asymptomatic. - <b>Medical:</b> Hydroxyurea was historically tried in
unresectable cases; more recently targeted inhibitors (like SMO inhibitors for
rare Hedgehog-mutated meningiomas, or bevacizumab) have been used in trials
especially for NF2 cases.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:pediatric-meningiomas'><b><span lang=EN>Prognosis:</span></b><span
lang=EN> Grade I meningiomas  excellent if resected. Atypical (grade II) have
recurrence risk ~40% in 5 years; anaplastic (grade III) behave aggressively.
Children, especially NF2 cases, often face multiple recurrences or new tumors
over time.</span></span></span></span></span></p>

<span style='mso-bookmark:pediatric-meningiomas'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><a
name=X933949c4ed009e610a5766637746532d6150893><span lang=EN>Mesenchymal CNS
Tumors (Intracranial Sarcomas)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span lang=EN>These
are rare. They include a variety of non-meningothelial mesenchymal tumors that
can arise in the CNS: - <b>Chordoma:</b> A malignant bone tumor from
clival/notochord remnants, often at skull base or sacrum. Rare in children, but
clival chordomas do occur in adolescents. - <b>Intracranial Mesenchymal Tumor,
FET-CREB fusion-positive:</b> New provisional entity (e.g. intracranial myxoid
mesenchymal tumor with EWSR1-FUS-CREB fusion). These are rare low-grade tumors
in young patients. - <b>CIC-rearranged sarcoma:</b> Highly malignant;
originally described in soft tissue as CIC-DUX4 sarcoma, but similar can arise
in CNS. Often presents like an embryonal tumor in children. - <b>Primary
intracranial sarcoma, DICER1-mutant:</b> Recognized in DICER1 syndrome patients
(or sporadic)  e.g. a child with DICER1 mutation can develop an intracranial
spindle cell sarcoma. - <b>Others:</b> Hemangiopericytoma (now called solitary
fibrous tumor) can occur (though usually adult). - <b>Hemangioblastoma:</b> a
vascular tumor associated with VHL disease, rarely in children unless they have
VHL (then teenagers can get cerebellar hemangioblastomas).</span></span></span></span></span></p>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><a name=chordoma><span
lang=EN>Chordoma</span></a></span></span></span></span></h4>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo39'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:chordoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Origin:</span></b><span
lang=EN> Skull base (clivus) or upper cervical chordomas can present in
childhood, though most chordomas are adult.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo39'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:chordoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Path:</span></b><span lang=EN>
Physaliferous (bubbly cytoplasm) cells in cords. Locally invasive into bone.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo39'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:chordoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Molecular:</span></b><span
lang=EN> Brachyury (T gene) is overexpressed (used as IHC marker).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo39'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:chordoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Treatment:</span></b><span
lang=EN> Surgery (often partial due to location) + proton beam radiation (high
dose ~74 Gy). No effective chemo.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo39'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:chordoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Outcome:</span></b><span
lang=EN> Tends to recur locally; 5-year survival for peds skull-base chordoma
~60-70%. With advanced RT, control improving.</span></span></span></span></span></span></p>

<span style='mso-bookmark:chordoma'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><a
name=Xb1552a0fae6647e2e5791478b2c0e892725a173><span lang=EN>Intracranial
Mesenchymal Tumor, FET-CREB fusion-positive</span></a></span></span></span></span></h4>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo40'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:Xb1552a0fae6647e2e5791478b2c0e892725a173'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Likely refers to what used to be
angiocentric myxoid mesenchymal tumor or similar  a low-grade neoplasm with
EWSR1-ATF1 or other fusions.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo40'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:Xb1552a0fae6647e2e5791478b2c0e892725a173'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Occurs in young patients, often
dura-based or intraventricular.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo40'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:Xb1552a0fae6647e2e5791478b2c0e892725a173'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Treated by resection; can recur
but generally indolent.</span></span></span></span></span></span></p>

<span style='mso-bookmark:Xb1552a0fae6647e2e5791478b2c0e892725a173'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><a
name=cic-rearranged-sarcoma><span lang=EN>CIC-rearranged Sarcoma</span></a></span></span></span></span></h4>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo41'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:cic-rearranged-sarcoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Presents like an embryonal brain
tumor (sometimes mistaken for AT/RT or ETMR). Often in cerebral hemispheres of
children or young adults.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo41'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:cic-rearranged-sarcoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Extremely aggressive and resistant
to therapy; in systemic cases median survival &lt;2 years.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo41'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:cic-rearranged-sarcoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>No established treatment;
typically try surgery, chemo (sarcoma or PNET-like regimens), and radiation.</span></span></span></span></span></span></p>

<span style='mso-bookmark:cic-rearranged-sarcoma'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><a
name=X6ab5bd7d63b76e3e685a11e1dd64ddf12461fb4><span lang=EN>Primary
Intracranial Sarcoma, DICER1-mutant</span></a></span></span></span></span></h4>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo42'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:X6ab5bd7d63b76e3e685a11e1dd64ddf12461fb4'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>DICER1 syndrome patients can
develop these (e.g. pineal region or supratentorial).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo42'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:X6ab5bd7d63b76e3e685a11e1dd64ddf12461fb4'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Pathologically can be a spindle
cell sarcoma or anaplastic primitive tumor.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo42'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:X6ab5bd7d63b76e3e685a11e1dd64ddf12461fb4'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Treated with surgery, chemo, RT
akin to other high-grade sarcomas.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo42'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:X6ab5bd7d63b76e3e685a11e1dd64ddf12461fb4'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Outcome variable; some long-term
survivors if localized.</span></span></span></span></span></span></p>

<span style='mso-bookmark:X6ab5bd7d63b76e3e685a11e1dd64ddf12461fb4'></span>

<h4><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><a
name=hemangioblastoma><span lang=EN>Hemangioblastoma</span></a></span></span></span></span></h4>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo43'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:hemangioblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Not truly a sarcoma, but a
vascular neoplasm (WHO grade 1). Occurs mostly in VHL disease (mutated VHL
gene). Can appear in teens with VHL (usually retinal hemangioblastomas first,
then CNS).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo43'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:hemangioblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Location: cerebellum (most
common), brainstem, or spinal cord.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo43'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:hemangioblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Presents with symptoms of mass
effect.</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo43'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:hemangioblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Treatment: Surgical removal is
usually curative (highly vascular but benign tumor). In VHL with multiple
lesions, often multiple surgeries or sometimes consider anti-angiogenic therapy
(like pazopanib, off-label).</span></span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo43'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:meningeal-and-mesenchymal-tumors'><span
style='mso-bookmark:X933949c4ed009e610a5766637746532d6150893'><span
style='mso-bookmark:hemangioblastoma'><![if !supportLists]><span lang=EN
style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><span lang=EN>Prognosis: Excellent for
individual tumor, but VHL patients get recurrences/new tumors over time.</span></span></span></span></span></span></p>

<span style='mso-bookmark:hemangioblastoma'></span><span style='mso-bookmark:
X933949c4ed009e610a5766637746532d6150893'></span><span style='mso-bookmark:
meningeal-and-mesenchymal-tumors'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=nerve-sheath-tumors><span lang=EN>Nerve
Sheath Tumors</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
lang=EN>Intracranial nerve sheath tumors in pediatrics are uncommon except in
genetic syndromes.</span></span></span></span></p>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><a
name=schwannomas-vestibular-schwannoma><span lang=EN>Schwannomas (Vestibular
Schwannoma)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:schwannomas-vestibular-schwannoma'><span lang=EN>Vestibular
schwannomas (acoustic neuromas) on CN VIII are classic in <b>NF2</b> patients,
who often present in late adolescence or young adulthood with hearing loss</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=NF2%20Schwannoma%2C%20meningioma%2C%20astrocytoma%2C%20ependymoma,Malignant%20peripheral%20nerve"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:schwannomas-vestibular-schwannoma'><span lang=EN>[116]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:schwannomas-vestibular-schwannoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:schwannomas-vestibular-schwannoma'><span lang=EN>. Sporadic
vestibular schwannomas in children are extremely rare.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:schwannomas-vestibular-schwannoma'><span lang=EN>Other
cranial nerve schwannomas (trigeminal, etc.) can occur in NF2 or sporadically
(very rare in kids).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:schwannomas-vestibular-schwannoma'><b><span lang=EN>Treatment:</span></b><span
lang=EN> - Observation is an option if small and hearing intact (especially in
NF2, one might delay intervention to preserve hearing). - Microsurgical removal
if growing or causing brainstem compression. - Stereotactic radiosurgery is
often used in adults; in NF2 kids, bevacizumab (VEGF antibody) has been shown
to shrink vestibular schwannomas and improve hearing in some cases (an
important medical therapy in NF2)  this can delay need for surgery</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=NF2%20Schwannoma%2C%20meningioma%2C%20astrocytoma%2C%20ependymoma,Malignant%20peripheral%20nerve"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:schwannomas-vestibular-schwannoma'><span lang=EN>[116]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:schwannomas-vestibular-schwannoma'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:schwannomas-vestibular-schwannoma'><span lang=EN>. -
Outcome: benign tumor, so not life-threatening unless untreated large tumor
causing brainstem compression. NF2 patients often have bilateral tumors.</span></span></span></span></span></p>

<span style='mso-bookmark:schwannomas-vestibular-schwannoma'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><a
name=other-nerve-sheath-tumors><span lang=EN>Other Nerve Sheath Tumors</span></a></span></span></span></h3>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo44'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:other-nerve-sheath-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Plexiform Neurofibromas:</span></b><span
lang=EN> Occur in NF1 patients, often in peripheral nerves (plexiform in neck,
brachial plexus, etc.). Occasionally NF1 can have intracranial nerve
neurofibromas (like optic pathway glioma is glial, not nerve sheath; but
trigeminal neurofibroma rarely).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo44'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:other-nerve-sheath-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Malignant Peripheral Nerve
Sheath Tumors (MPNST):</span></b><span lang=EN> Very rare intracranially
(usually peripheral). NF1 patients can develop MPNST from plexiforms, usually
in body, not in brain.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo44'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:other-nerve-sheath-tumors'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>Schwannomatosis (SMARCB1/LZTR1
mutations):</span></b><span lang=EN> multiple non-vestibular schwannomas; can
include intracranial nerves. Typically adult onset.</span></span></span></span></span></p>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:nerve-sheath-tumors'><span
style='mso-bookmark:other-nerve-sheath-tumors'><span lang=EN>In summary, nerve
sheath tumors in pediatric CNS are largely NF2-associated vestibular
schwannomas and maybe trigeminal schwannomas. These require multidisciplinary
management (neurosurgery, ENT, audiology, sometimes Avastin therapy).</span></span></span></span></span></p>

<span style='mso-bookmark:other-nerve-sheath-tumors'></span><span
style='mso-bookmark:nerve-sheath-tumors'></span>

<h2><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><a name=tumor-predisposition-syndromes><span
lang=EN>Tumor Predisposition Syndromes</span></a></span></span></h2>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
lang=EN>Certain hereditary syndromes greatly increase the risk of pediatric CNS
tumors. Recognizing them is crucial for appropriate screening and management</span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=skin%20examination%20is%20important%20to,responsible%20for%20repairing%20a%20specific"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
lang=EN>[117]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'></span></span></span></a><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=type%201%20%28predisposed%20to%20low,damage%20known%20as%20mismatch%20repair"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
lang=EN>[118]</span></span></span></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
lang=EN>. Key syndromes:</span></span></span></span></p>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=neurofibromatosis-type-1-nf1><span lang=EN>Neurofibromatosis Type 1 (NF1)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><b><span lang=EN>Gene:</span></b><span
lang=EN> NF1 (17q)  tumor suppressor encoding neurofibromin (Ras regulator).
Autosomal dominant.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><b><span lang=EN>CNS tumor
associations:</span></b><span lang=EN> NF1 patients frequently develop <b>optic
pathway gliomas</b> (pilocytic astrocytomas of the optic nerve/chiasm)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=skin%20examination%20is%20important%20to,responsible%20for%20repairing%20a%20specific"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><span lang=EN>[117]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><span lang=EN>. These occur
in early childhood. They can also get other brain gliomas (astrocytomas
elsewhere, brainstem gliomas) and have higher risk of malignant peripheral
nerve sheath tumors (though those are peripheral). NF1-associated gliomas are
usually low-grade (JPA), but occasionally can be higher grade in teens.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><b><span lang=EN>Features:</span></b><span
lang=EN> Caf-au-lait macules, axillary/inguinal freckling, cutaneous
neurofibromas, Lisch nodules in iris, etc. Learning disabilities common.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><b><span lang=EN>Screening/management:</span></b><span
lang=EN> Yearly ophthalmology exams in childhood for OPG. If symptomatic OPG
(vision loss), treat with chemo (usually carboplatin/vincristine or now often
MEK inhibitors like selumetinib)  NF1 gliomas often respond to MEK inhibitors</span></span></span></span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=gliomas%20,challenge%20in%20a%20group%20of"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><span lang=EN>[3]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><span lang=EN>. NF1 gliomas
tend to stabilize after puberty.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><i><span lang=EN>(Citations:
NF1 predisposes to low-grade gliomas, especially optic gliomas</span></i></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=NF1%20Low,Malignant%20peripheral%20nerve%20sheath%20tumor"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><i><span lang=EN>[119]</span></i></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-1-nf1'><i><span lang=EN>.)</span></i></span></span></span></span></p>

<span style='mso-bookmark:neurofibromatosis-type-1-nf1'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=neurofibromatosis-type-2-nf2><span lang=EN>Neurofibromatosis Type 2 (NF2)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><b><span lang=EN>Gene:</span></b><span
lang=EN> NF2 (22q)  encodes Merlin. Autosomal dominant.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><b><span lang=EN>CNS tumors:</span></b><span
lang=EN> Hallmark is <b>bilateral vestibular schwannomas</b> (acoustic
neuromas) typically by young adulthood</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=NF2%20Schwannoma%2C%20meningioma%2C%20astrocytoma%2C%20ependymoma,Malignant%20peripheral%20nerve"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><span lang=EN>[116]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><span lang=EN>. Also multiple
meningiomas and spinal ependymomas</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=NF2%20Schwannoma%2C%20meningioma%2C%20astrocytoma%2C%20ependymoma,Malignant%20peripheral%20nerve"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><span lang=EN>[116]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><span lang=EN>. Can also get
other cranial nerve schwannomas.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><b><span lang=EN>Features:</span></b><span
lang=EN> Bilateral hearing loss in teens/20s, meningiomas causing seizures or
deficits, skin schwannomas (but fewer caf-au-lait than NF1).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><b><span lang=EN>Management:</span></b><span
lang=EN> Annual MRI screening of brain and spine from teenage years. Treat
tumors individually (surgery or radiosurgery). Bevacizumab can cause vestibular
schwannomas to shrink and improve hearing in NF2</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Schwannomatosis%20SMARCB1%20,LZTR1%20Schwannoma%2C%20meningioma%20SMARCB1%3A%20malignant"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><span lang=EN>[120]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><span lang=EN> (Merlin
pathway influences VEGF).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><i><span lang=EN>(Citations:
NF2 predisposes to schwannomas, meningiomas, ependymomas</span></i></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=NF2%20Schwannoma%2C%20meningioma%2C%20astrocytoma%2C%20ependymoma,Malignant%20peripheral%20nerve"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><i><span lang=EN>[116]</span></i></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:neurofibromatosis-type-2-nf2'><i><span lang=EN>.)</span></i></span></span></span></span></p>

<span style='mso-bookmark:neurofibromatosis-type-2-nf2'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=tuberous-sclerosis-complex-tsc><span lang=EN>Tuberous Sclerosis Complex
(TSC)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'><b><span lang=EN>Genes:</span></b><span
lang=EN> TSC1 (hamartin) or TSC2 (tuberin). AD, though many de novo.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'><b><span lang=EN>CNS
tumors:</span></b><span lang=EN> <b>Subependymal Giant Cell Astrocytoma (SEGA)</b>
in up to 10-15% of patients</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=TSC1%2C%20TSC2%20Subependymal%20giant%20cell,astrocytoma%20Renal%20angiomyolipoma%2C%20cardiac%20rhabdomyoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'><span lang=EN>[12]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'><span lang=EN>. These arise
in lateral ventricles near Monro and can cause hydrocephalus. Also cortical
tubers (developmental hamartomas causing epilepsy) and subependymal nodules.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'><b><span lang=EN>Features:</span></b><span
lang=EN> Skin (facial angiofibromas, ash-leaf spots, Shagreen patch), epilepsy
(infantile spasms often), cognitive impairment, renal angiomyolipomas, cardiac
rhabdomyomas</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=TSC1%2C%20TSC2%20Subependymal%20giant%20cell,astrocytoma%20Renal%20angiomyolipoma%2C%20cardiac%20rhabdomyoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'><span lang=EN>[12]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'><b><span lang=EN>Management:</span></b><span
lang=EN> Monitor via MRI for SEGA growth (especially in childhood/adolescence).
Treat growing SEGAs with <b>everolimus (mTOR inhibitor)</b>  often shrinks
tumor and can obviate surgery</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=TSC1%2C%20TSC2%20Subependymal%20giant%20cell,astrocytoma%20Renal%20angiomyolipoma%2C%20cardiac%20rhabdomyoma"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'><span lang=EN>[12]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:tuberous-sclerosis-complex-tsc'><span lang=EN>. Epilepsy
management (often surgery for tubers or newer drugs like everolimus can help
seizures too).</span></span></span></span></span></p>

<span style='mso-bookmark:tuberous-sclerosis-complex-tsc'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=li-fraumeni-syndrome-lfs><span lang=EN>Li-Fraumeni Syndrome (LFS)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><b><span lang=EN>Gene:</span></b><span
lang=EN> TP53 (p53) germline mutation. AD.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><b><span lang=EN>CNS tumors:</span></b><span
lang=EN> High propensity for <b>high-grade gliomas</b> (especially in
childhood, e.g. glioblastoma) and <b>Choroid plexus carcinomas</b>
(particularly in infants, CPC is a classic LFS tumor)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Li,Sarcomas%2C%20adrenocortical%20carcinoma%2C%20breast%20cancer"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><span lang=EN>[55]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><span lang=EN>. Also can see
medulloblastoma (SHH subgroup with TP53-mutant)</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%80%A2%20Most%20common%20in%20children,activated%20medulloblastomas"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><span lang=EN>[61]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><b><span lang=EN>Features:</span></b><span
lang=EN> Very broad cancer spectrum (sarcomas, breast cancer, leukemia,
adrenocortical carcinoma, etc.) at young ages.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><b><span lang=EN>Management:</span></b><span
lang=EN> Intense surveillance (per Toronto protocol for LFS). Avoid radiation
if possible (since radiation-induced cancers are a risk). If a child of LFS
family presents with CPC or HGG, LFS should be suspected.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><i><span lang=EN>(Citations: TP53
(LFS) predisposes to gliomas, medulloblastomas, choroid plexus carcinoma</span></i></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Li,Sarcomas%2C%20adrenocortical%20carcinoma%2C%20breast%20cancer"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><i><span lang=EN>[55]</span></i></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:li-fraumeni-syndrome-lfs'><i><span lang=EN>.)</span></i></span></span></span></span></p>

<span style='mso-bookmark:li-fraumeni-syndrome-lfs'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=Xd5479182ada802bea2f9018982bc9b3754420df><span lang=EN>Gorlin Syndrome
(Nevoid Basal Cell Carcinoma Syndrome)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><b><span lang=EN>Genes:</span></b><span
lang=EN> PTCH1 (mostly) or SUFU. AD.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><b><span lang=EN>CNS
tumors:</span></b><span lang=EN> Predisposes to <b>medulloblastoma, SHH subtype</b></span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Gorlin%20PTCH1%2C%20SUFU%20Medulloblastoma%20,symptomatic%20SUFU%3A%20Consider%20screening%20if"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><span lang=EN>[121]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><span lang=EN>.
Specifically, infants with Gorlin have ~5% risk of medulloblastoma (usually
desmoplastic nodular subtype SHH). SUFU mutation carriers have an even higher
medullo risk in infancy (up to 20%).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><b><span lang=EN>Features:</span></b><span
lang=EN> Multiple basal cell carcinomas (especially after radiation, so avoid
XRT), jaw keratocysts, calcification of falx, bifid ribs, etc</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%17Gorlin%20syndrome%20,Germline%20PTCH1%20and%20SUFU%20mutations"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><span lang=EN>[76]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><span lang=EN>.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><b><span lang=EN>Management:</span></b><span
lang=EN> If a medulloblastoma patient has Gorlin (or germline SUFU), one
crucial point is <b>avoid cranial radiation</b> if possible (because they will
get hundreds of BCC skin cancers in radiation field). Therefore, treat with
surgery and chemo only, or proton therapy to minimize dose, and rigorous skin
monitoring. For PTCH1 Gorlin kids, use chemo-intensive protocols for medullo to
delay/avoid RT.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><i><span lang=EN>(Citations:
Gorlin syndrome (PTCH1, SUFU) predisposes to SHH medulloblastomas</span></i></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%28Gorlin%20syndrome%29%20SHH,activated%20medulloblastomas"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><i><span lang=EN>[60]</span></i></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'><i><span lang=EN>.)</span></i></span></span></span></span></p>

<span style='mso-bookmark:Xd5479182ada802bea2f9018982bc9b3754420df'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=turcot-syndrome-fap-and-lynch-subtypes><span lang=EN>Turcot Syndrome (FAP
and Lynch subtypes)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'><span lang=EN>Turcot
refers to familial polyposis syndromes with CNS tumor predisposition: - <b>APC
gene mutation (Familial Adenomatous Polyposis)</b>  associated with
medulloblastoma (usually WNT subtype)</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=match%20at%20L2216%20%E2%97%8A%20Associated,hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'><span lang=EN>[122]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'><span lang=EN>. In
childhood, if a FAP patient develops a brain tumor, its classically
medulloblastoma. This is sometimes called Turcot Type 2. - <b>Mismatch Repair
gene mutations (Lynch syndrome or Constitutional MMR-D)</b>  associated with
high-grade gliomas (astrocytomas/GBM) in children</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=match%20at%20L2216%20%E2%97%8A%20Associated,hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'><span lang=EN>[122]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'><span lang=EN>.
Constitutional MMR deficiency (biallelic Lynch mutations) often causes
childhood glioblastomas (and leukemias, early GI cancers)  sometimes referred
to as Turcot Type 1.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'><b><span lang=EN>Management:</span></b><span
lang=EN> For APC carriers, standard medulloblastoma treatment (they tolerate
therapy normally). For CMMRD patients, treat HGG as usual but they have extreme
toxicity to alkylators (and radiation) and often second cancers, so its very
challenging.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'><i><span lang=EN>(Citations:
APC/FAP predisposes to medulloblastoma; Lynch/CMMRD to high-grade gliomas</span></i></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=match%20at%20L2216%20%E2%97%8A%20Associated,hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'><i><span lang=EN>[122]</span></i></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'><i><span lang=EN>.)</span></i></span></span></span></span></p>

<span style='mso-bookmark:turcot-syndrome-fap-and-lynch-subtypes'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=X777dc7e045bea7d2422726c7cdef6d5ff877be3><span lang=EN>Rhabdoid Tumor
Predisposition (SMARCB1/SMARCA4 mutations)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'><span lang=EN>Germline
mutation of SMARCB1 (INI1) causes <b>Rhabdoid Tumor Predisposition Syndrome</b>.
Affected infants can develop ATRT in the brain and/or rhabdoid tumors in kidney
(RTK) or other sites.</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo45'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>SMARCB1</span></b><span
lang=EN> mutation: Often new in the child (parents phenotypically normal).</span></span></span></span></span></p>

<p class=Compact style='margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo45'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'><![if !supportLists]><span
lang=EN style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
Symbol'><span style='mso-list:Ignore'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span></span><![endif]><b><span lang=EN>SMARCA4</span></b><span
lang=EN> germline: Causes a syndrome of ovarian small cell carcinoma in females
and ATRT-like tumors.</span></span></span></span></span></p>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'><b><span lang=EN>Management:</span></b><span
lang=EN> If an infant presents with ATRT, germline testing is indicated (up to
35% have germline SMARCB1/4)</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Histologically%2C%20the%20loss%20of%20INI1%2C,to%20the%20development%20of%20malignant"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'><span lang=EN>[80]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'><span lang=EN>.
Family planning and sibling testing can be done as well. No preventive measures
except vigilant early imaging if known mutation.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'><i><span lang=EN>(Citations:
35% of ATRT patients have germline SMARCB1/SMARCA4</span></i></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Histologically%2C%20the%20loss%20of%20INI1%2C,to%20the%20development%20of%20malignant"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'><i><span lang=EN>[80]</span></i></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'><i><span lang=EN>.)</span></i></span></span></span></span></p>

<span style='mso-bookmark:X777dc7e045bea7d2422726c7cdef6d5ff877be3'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=dicer1-syndrome><span lang=EN>DICER1 Syndrome</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:dicer1-syndrome'><span lang=EN>Germline DICER1 mutation
leads to a tumor predisposition syndrome with a variety of rare tumors: - CNS: <b>Pineoblastoma</b>
(DICER1 is found in ~20% of pineoblastomas), <b>Pituitary blastoma</b>, and <b>intracranial
sarcoma</b> with DICER1 mutation. - Others: Pleuropulmonary blastoma (lung),
cystic nephroma, ovarian Sertoli-Leydig cell tumors, thyroid goiter or
carcinoma.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:dicer1-syndrome'><b><span lang=EN>Management:</span></b><span
lang=EN> If child with pineoblastoma or pituitary blastoma, consider DICER1
testing. Typically inherited in families with other DICER1 tumors. Surveillance
recommendations exist (chest imaging for lung tumor, US for thyroid etc.).</span></span></span></span></span></p>

<span style='mso-bookmark:dicer1-syndrome'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=cowden-syndrome-pten-hamartoma-syndrome><span lang=EN>Cowden Syndrome
(PTEN Hamartoma Syndrome)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:cowden-syndrome-pten-hamartoma-syndrome'><b><span lang=EN>Gene:</span></b><span
lang=EN> PTEN (AD). <b>CNS association:</b> <b>Dysplastic gangliocytoma of
cerebellum (Lhermitte-Duclos disease)</b>  essentially a hamartomatous
overgrowth in cerebellum that can cause mass effect in young adults (rare in
actual kids). PTEN mutations also slightly raise risk of other brain tumors
(some gliomas reported) but not a strong link like others above. <b>Features:</b>
Macrocephaly, trichilemmomas, breast/thyroid/endometrial cancers.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:cowden-syndrome-pten-hamartoma-syndrome'><b><span lang=EN>Management:</span></b><span
lang=EN> MRI if LDD suspected. Otherwise no routine brain screening beyond
clinical exam.</span></span></span></span></span></p>

<span style='mso-bookmark:cowden-syndrome-pten-hamartoma-syndrome'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=von-hippellindau-vhl-disease><span lang=EN>Von HippelLindau (VHL) Disease</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:von-hippellindau-vhl-disease'><b><span lang=EN>Gene:</span></b><span
lang=EN> VHL (AD). <b>CNS tumors:</b> <b>Hemangioblastomas</b> of cerebellum,
brainstem, spinal cord  typically starting in teenage years or 20s</span></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=medulloblastoma%2C%20hemangioblastoma%20Leukemia%2C%20gastrointestinal%20tumors%2C,others"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:von-hippellindau-vhl-disease'><span lang=EN>[123]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:von-hippellindau-vhl-disease'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:von-hippellindau-vhl-disease'><span lang=EN>. Also
endolymphatic sac tumors in inner ear. <b>Features:</b> Retinal
hemangioblastomas (vision loss), renal clear cell carcinoma, pheochromocytoma,
pancreatic cysts/neuroendocrine tumors. <b>Management:</b> Annual MRI from
adolescence. Remove hemangioblastomas when symptomatic (to prevent neuro
deficits). They can recur/new ones form lifelong.</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:von-hippellindau-vhl-disease'><i><span lang=EN>(Citations:
VHL can present with medulloblastoma and hemangioblastomas in some contexts</span></i></span></span></span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=match%20at%20L871%20medulloblastoma%2C%20hemangioblastoma,Leukemia%2C%20gastrointestinal%20tumors%2C%20others"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:von-hippellindau-vhl-disease'><i><span lang=EN>[124]</span></i></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:von-hippellindau-vhl-disease'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:von-hippellindau-vhl-disease'><i><span lang=EN>  though
medulloblastoma link is less direct, sometimes mentioned historically,
hemangioblastomas are classic.)</span></i></span></span></span></span></p>

<span style='mso-bookmark:von-hippellindau-vhl-disease'></span>

<h3><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><a
name=X8190de060ffe98da450190550a941f1cb41bb78><span lang=EN>Constitutional
Mismatch Repair Deficiency (CMMRD)</span></a></span></span></span></h3>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><span lang=EN>This
is essentially the biallelic form of Lynch syndrome  inheriting two mutated
MMR genes (PMS2, MLH1, MSH2, MSH6). <b>CNS tumors:</b> Very high risk of
childhood glioblastomas (often multiple), sometimes Lynch syndrome type brain
tumor called gliomatosis. Also hematologic malignancies, and GI cancers in
childhood. <b>Features:</b> Caf-au-lait spots (can mimic NF1), consanguinity
often in parents, childhood cancers. <b>Management:</b> Extremely difficult,
but hypermutability means they sometimes respond to immunotherapy (PD-1
inhibitors) in trials. Avoid alkylator chemo if possible (they often fail it
anyway).</span></span></span></span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><i><span lang=EN>(Turcot
syndrome type was historically applied to CMMRD for glioma predisposition</span></i></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%97%8A%20Associated%20with%20colon%20cancer%2C,hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><i><span lang=EN>[59]</span></i></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><i><span lang=EN>.)</span></i></span></span></span></span></p>

<div class=MsoNormal align=center style='text-align:center'><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><span lang=EN
style='mso-no-proof:yes'>

<hr size=0 width="100%" align=center>

</span></span></span></span></span></div>

<p class=FirstParagraph><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><b><span lang=EN>Conclusion:</span></b><span
lang=EN> This reference has compiled the spectrum of pediatric CNS tumors per
the WHO 2021 classification (including newly defined entities)</span></span></span></span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Newly%20Recognized%20Tumor%20Types%20Diffuse,provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><span lang=EN>[5]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'></span></span></span></span></a><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Supratentorial%20ependymoma%2C%20YAP1%20fusion,CREB%20fusion%20positive%C2%A0%28provisional%20type"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><span lang=EN>[125]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><span lang=EN>,
along with key diagnostic criteria (clinical presentation, imaging, histology,
molecular markers) and standard treatments drawn from current protocols (NCCN,
COG, SIOP, etc.). Pediatric brain tumor management is increasingly
risk-adapted, incorporating molecular features into therapy decisions</span></span></span></span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=therapies%20in%20patients%20whose%20tumors,artificial%20intelligence%20model%20or%20tool"><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><span lang=EN>[126]</span></span></span></span></span><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'></span></span></span></span></a><span
style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'><span
style='mso-bookmark:content'><span style='mso-bookmark:tumor-predisposition-syndromes'><span
style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'><span lang=EN>.
Multidisciplinary care and attention to long-term effects (endocrine,
neurocognitive, etc.) are essential for survivors. All data is up-to-date as of
2025 and sourced from authoritative guidelines and studies.</span></span></span></span></span></p>

<span style='mso-bookmark:X8190de060ffe98da450190550a941f1cb41bb78'></span><span
style='mso-bookmark:tumor-predisposition-syndromes'></span><span
style='mso-bookmark:content'></span><span style='mso-bookmark:Xb575b9c3c2a588539640afd7a5ef21f8a9601f7'></span>

<div class=MsoNormal align=center style='text-align:center'><span lang=EN
style='mso-no-proof:yes'>

<hr size=0 width="100%" align=center>

</span></div>

<p class=FirstParagraph><a name=citations></a><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20Low%20Grade%20Glioma%20Introduction%3A,14%2C%2015%29%2C%20otherwise"><span
style='mso-bookmark:citations'><span lang=EN>[1]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Vinblastine%205%20mg%2Fm2,vinblastine%20monotherapy%20protocol%20for%20details"><span
style='mso-bookmark:citations'><span lang=EN>[8]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Low%20Grade%20Glioma%201st%20Line,with%20additional%20IT%20chemotherapy"><span
style='mso-bookmark:citations'><span lang=EN>[9]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Low%20Grade%20Glioma%201st%20Line,per%20ACNS0331%20with%20boost%20to"><span
style='mso-bookmark:citations'><span lang=EN>[10]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20Low%20Grade%20Glioma%20Introduction%3A,14%2C%2015%29%2C%20otherwise"><span
style='mso-bookmark:citations'><span lang=EN>[11]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20High%20Grade%20Glioma%20Overview%3A,pdf%20page%205%20of%2015"><span
style='mso-bookmark:citations'><span lang=EN>[22]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=2nd%20Line%20%E2%80%A2%20Targeted%20inhibitor,with%20additional%20IT%20chemotherapy"><span
style='mso-bookmark:citations'><span lang=EN>[23]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Maximal%20safe%20surgical,Chemotherapy%20is%20given%20as"><span
style='mso-bookmark:citations'><span lang=EN>[25]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Focal%20radiation%20therapy,common%20malignant%20brain%20tumor%20of"><span
style='mso-bookmark:citations'><span lang=EN>[26]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=VCR%2FCarboplatin%20,with%20additional%20IT%20chemotherapy"><span
style='mso-bookmark:citations'><span lang=EN>[31]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20The%20approach%20includes,8%20Gy%20with%20concurrent"><span
style='mso-bookmark:citations'><span lang=EN>[33]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=In%20certain%20tumors%2C%20the%20molecular,in%20a%20variety%20of%20tumors"><span
style='mso-bookmark:citations'><span lang=EN>[48]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=HR%20%E2%80%A2%20Chemotherapy%20per%2099703,with%20WVI%20%C2%B1%20boost%20to"><span
style='mso-bookmark:citations'><span lang=EN>[50]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Pediatric%20High%20Grade%20Glioma%20Overview%3A,943%20randomized"><span
style='mso-bookmark:citations'><span lang=EN>[53]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Spinal%20EPN%20%28SP,19"><span
style='mso-bookmark:citations'><span lang=EN>[54]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Infant%20Medulloblastoma%20AR%20%E2%80%A2%20Chemotherapy,%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay%20radiation"><span
style='mso-bookmark:citations'><span lang=EN>[71]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Childhood%20Medulloblastoma%20AR%20%E2%80%A2%20Radiation%2Fchemotherapy,%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay%20radiation"><span
style='mso-bookmark:citations'><span lang=EN>[72]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=High%20Grade%20Glioma%20%E2%80%A2%20Chemotherapy%2Fradiation,%2B%2F%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay"><span
style='mso-bookmark:citations'><span lang=EN>[73]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20Maximal%20safe%20surgical,CCG%2099703"><span
style='mso-bookmark:citations'><span lang=EN>[81]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=VCR%2FCarboplatin%20,19"><span
style='mso-bookmark:citations'><span lang=EN>[82]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Ependymoma%20Localized%20%E2%80%A2%20Focal%20radiation,%E2%88%92%20maintenance%20chemotherapy%2C%20avoid%2Fdelay%20radiation"><span
style='mso-bookmark:citations'><span lang=EN>[83]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=%28112%2C%20114%E2%80%93116%29,in%20the%20serum%20and%20lumbar"><span
style='mso-bookmark:citations'><span lang=EN>[85]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Tumors%20Introduction%3A%20Primary%20intracranial%20germ,affecting%20both%20the%20pineal%20and"><span
style='mso-bookmark:citations'><span lang=EN>[86]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=are%20predominantly%20located%20in%20the,decade%20of%20life%2C%20and%20in"><span
style='mso-bookmark:citations'><span lang=EN>[87]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=%28112%2C%20114%E2%80%93116%29,decade%20of%20life%2C%20and%20in"><span
style='mso-bookmark:citations'><span lang=EN>[88]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Asia%20%282%2C%20112%2C%20113%2C%20115%29,113"><span
style='mso-bookmark:citations'><span lang=EN>[89]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=commonly%20germinomas%20%28113%29,113"><span
style='mso-bookmark:citations'><span lang=EN>[90]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=ATRT%20%E2%80%A2%20Chemotherapy%20per%2099703,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:citations'><span lang=EN>[92]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=radiation%20Germinoma%20Localized%20%E2%80%A2%20Chemotherapy,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:citations'><span lang=EN>[93]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=ATRT%20%E2%80%A2%20Chemotherapy%20per%2099703,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:citations'><span lang=EN>[94]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=radiation%20Germinoma%20Localized%20%E2%80%A2%20Chemotherapy,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:citations'><span lang=EN>[95]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20SIOP%20CNS%20GCT,with%20CSI%20for%20all%20patients"><span
style='mso-bookmark:citations'><span lang=EN>[96]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Germinoma%20Localized%20%E2%80%A2%20Chemotherapy%20per,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:citations'><span lang=EN>[97]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=tumor%20Disseminated%20%E2%80%A2%20Chemotherapy%20per,22%29%20with%20craniospinal%20radiation"><span
style='mso-bookmark:citations'><span lang=EN>[98]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Craniopharyngioma%20Introduction%3A%20Craniopharyngiomas%20,of%20the%20most%20frequently%20diagnosed"><span
style='mso-bookmark:citations'><span lang=EN>[99]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=100%29,101"><span
style='mso-bookmark:citations'><span lang=EN>[100]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=are%20predominantly%20diagnosed%20with%20the,101"><span
style='mso-bookmark:citations'><span lang=EN>[101]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=proximity%20to%20critical%20structures%20surrounding,whereas%20adults%20typically"><span
style='mso-bookmark:citations'><span lang=EN>[102]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=adenohypophysis%20%2896%29,predominantly%20diagnosed%20with%20the%20adamantinomatous"><span
style='mso-bookmark:citations'><span lang=EN>[103]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=mutations%20%28101%29,There%20are"><span
style='mso-bookmark:citations'><span lang=EN>[104]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20,20"><span
style='mso-bookmark:citations'><span lang=EN>[105]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=beneficial%20%28102%29,need%20for%20surgery%20and%20radiation"><span
style='mso-bookmark:citations'><span lang=EN>[106]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=institutions%20have%20been%20using%20intracystic,comes%20from%20the%20premise%20that"><span
style='mso-bookmark:citations'><span lang=EN>[107]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=amendable%20to%20the%20safe%20endoscopic,recognized%20to%20have%20anti%EF%BF%BEproliferative%20and"><span
style='mso-bookmark:citations'><span lang=EN>[108]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=demonstrate%20in%20their%20respective%20cohorts,recognized%20to%20have%20anti%EF%BF%BEproliferative%20and"><span
style='mso-bookmark:citations'><span lang=EN>[109]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=carcinomas%20where%20this%20agent%20is,two%20approaches%20are%20summarized%20below"><span
style='mso-bookmark:citations'><span lang=EN>[110]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=intracystic%20catheters%20and%20IFN%20instillation,Treatment%20Plan"><span
style='mso-bookmark:citations'><span lang=EN>[111]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=Treatment%20Plan%3A%20,Central%20Nervous%20System%20Germ%20Cell"><span
style='mso-bookmark:citations'><span lang=EN>[112]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=treatment%20is%20safe%20surgical%20resection%3B,102"><span
style='mso-bookmark:citations'><span lang=EN>[113]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_0000000025e461f5ae933fe46926882d#:~:text=a%20complete%20resection,safe%20endoscopic%20insertion%20of%20indwelling"><span
style='mso-bookmark:citations'><span lang=EN>[114]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> fonc-10-593192.pdf</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_0000000025e461f5ae933fe46926882d"><span style='mso-bookmark:
citations'><span lang=EN>file://file_0000000025e461f5ae933fe46926882d</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=also%20revealed%20important%20dif%EF%BF%BEferences%20between,While%20targeted%20therapy%20trials"><span
style='mso-bookmark:citations'><span lang=EN>[2]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=gliomas%20,challenge%20in%20a%20group%20of"><span
style='mso-bookmark:citations'><span lang=EN>[3]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=Pediatric%20brain%20tumors%20are%20the,These%20findings%20have"><span
style='mso-bookmark:citations'><span lang=EN>[16]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af#:~:text=ATRT%20tumors%20are%20characterized%20by,there%20is%20global%20loss%20of"><span
style='mso-bookmark:citations'><span lang=EN>[79]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> 1-s2.0-S0147027221000945-main.pdf</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_00000000dcd4622f8e9da97590c278af"><span style='mso-bookmark:
citations'><span lang=EN>file://file_00000000dcd4622f8e9da97590c278af</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Pediatric,neuroepithelial%20tumor%20of%20the%20young"><span
style='mso-bookmark:citations'><span lang=EN>[4]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Newly%20Recognized%20Tumor%20Types%20Diffuse,provisional%20type"><span
style='mso-bookmark:citations'><span lang=EN>[5]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Diffuse%20astrocytoma%2C%20MYB,provisional%20type"><span
style='mso-bookmark:citations'><span lang=EN>[6]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Pediatric,to%20their%20more%20solid%20growth"><span
style='mso-bookmark:citations'><span lang=EN>[7]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Infant,amplified"><span
style='mso-bookmark:citations'><span lang=EN>[13]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Diffuse%20glioneuronal%20tumor%20with%20oligodendroglioma,provisional%20type"><span
style='mso-bookmark:citations'><span lang=EN>[14]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L906%20the%20table%3A,positive"><span
style='mso-bookmark:citations'><span lang=EN>[15]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Pediatric,wildtype"><span
style='mso-bookmark:citations'><span lang=EN>[17]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Pediatric,wildtype"><span
style='mso-bookmark:citations'><span lang=EN>[18]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Polymorphous%20low,Myxoid%20glioneuronal%20tumor"><span
style='mso-bookmark:citations'><span lang=EN>[19]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=information,35%20Astroblastoma"><span
style='mso-bookmark:citations'><span lang=EN>[20]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=confuse%20clinical%20care%20,current%20therapeutic%20regi%EF%BF%BEmens%20such%20that"><span
style='mso-bookmark:citations'><span lang=EN>[27]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=embryonal%20tumor%20that%20has%20an,current%20therapeutic%20regi%EF%BF%BEmens%20such%20that"><span
style='mso-bookmark:citations'><span lang=EN>[28]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=the%20diffuse%20midline%20glioma%20is,35%20Astroblastoma"><span
style='mso-bookmark:citations'><span lang=EN>[29]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L463%20Supratentorial%20ependymomas,activated%20CTNNB1%2C%20APC"><span
style='mso-bookmark:citations'><span lang=EN>[30]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Diffuse%20hemispheric%20glioma%2C%20H3%20G34,grade%20astrocytoma%20with%20piloid%20features"><span
style='mso-bookmark:citations'><span lang=EN>[32]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Ependymomas,molecular%20groups%20across%20the%20supratentorial"><span
style='mso-bookmark:citations'><span lang=EN>[36]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L1248%20ependymoma%2C%20group,pdf%20page%2017%20of%2021"><span
style='mso-bookmark:citations'><span lang=EN>[37]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Supratentorial%20ependymoma%20Supratentorial%20ependymoma%2C%20ZFTA,positive%20Posterior%20fossa%20ependymoma"><span
style='mso-bookmark:citations'><span lang=EN>[38]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L248%20Posterior%20fossa,amplified"><span
style='mso-bookmark:citations'><span lang=EN>[39]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Posterior%20fossa%20ependymoma%2C%20group%20PFA,amplified"><span
style='mso-bookmark:citations'><span lang=EN>[40]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=now%20understood%20to%20be%20similar,Papillary%2C%20clear%20cell%2C%20and"><span
style='mso-bookmark:citations'><span lang=EN>[41]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L1270%20subtypes%20of,clinicopathological%20utility%20of%20grading%20ependymal"><span
style='mso-bookmark:citations'><span lang=EN>[42]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L1265%20classifications%2C%20the,Papillary%2C%20clear%20cell%2C%20and"><span
style='mso-bookmark:citations'><span lang=EN>[43]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=subtypes%20of%20ependymoma%2C%20being%20included,clinicopathological%20utility%20of%20grading%20ependymal"><span
style='mso-bookmark:citations'><span lang=EN>[44]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=ependymoma%E2%80%9D%20is%20no%20longer%20listed,according%20to%20its%20histopathological%20features"><span
style='mso-bookmark:citations'><span lang=EN>[45]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=match%20at%20L1281%20ependymoma%E2%80%9D%20is,according%20to%20its%20histopathological%20features"><span
style='mso-bookmark:citations'><span lang=EN>[46]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=supratentorial%20ependymoma%3A%20one%20with%20ZFTA,fusion%20and%20another"><span
style='mso-bookmark:citations'><span lang=EN>[49]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Supratentorial%20ependymomas%20ZFTA%2C%20RELA%2C%20YAP1%2C,activated%20CTNNB1%2C%20APC"><span
style='mso-bookmark:citations'><span lang=EN>[51]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Multinodular%20and%20vacuolating%20neuronal%20tumor,mutant"><span
style='mso-bookmark:citations'><span lang=EN>[52]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Cribriform%20neuroepithelial%20tumor%20,pdf%20page%2012%20of%2021"><span
style='mso-bookmark:citations'><span lang=EN>[56]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Supratentorial%20ependymoma%2C%20ZFTA%20fusion,to%20allow%20for%20genetic%20subtypes"><span
style='mso-bookmark:citations'><span lang=EN>[84]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000b210622fbb887bf691563cbf#:~:text=Supratentorial%20ependymoma%2C%20YAP1%20fusion,CREB%20fusion%20positive%C2%A0%28provisional%20type"><span
style='mso-bookmark:citations'><span lang=EN>[125]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> WHO_2021s.pdf</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_00000000b210622fbb887bf691563cbf"><span style='mso-bookmark:
citations'><span lang=EN>file://file_00000000b210622fbb887bf691563cbf</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=TSC1%2C%20TSC2%20Subependymal%20giant%20cell,astrocytoma%20Renal%20angiomyolipoma%2C%20cardiac%20rhabdomyoma"><span
style='mso-bookmark:citations'><span lang=EN>[12]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Li,Sarcomas%2C%20adrenocortical%20carcinoma%2C%20breast%20cancer"><span
style='mso-bookmark:citations'><span lang=EN>[55]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Medulloblastoma%20has%20been%20classified%20into,metastatic%20and%20have%20the%20best"><span
style='mso-bookmark:citations'><span lang=EN>[57]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=%28Table%203%29.%20%287%29%20WNT,metastatic%20and%20have%20the%20best"><span
style='mso-bookmark:citations'><span lang=EN>[58]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Medulloblastoma%20is%20divided%20into%204,there%20is%20molecular%20and%20clinical"><span
style='mso-bookmark:citations'><span lang=EN>[62]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=or%20nodular%20desmoplastic,Recent%20trials"><span
style='mso-bookmark:citations'><span lang=EN>[75]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Histologically%2C%20the%20loss%20of%20INI1%2C,to%20the%20development%20of%20malignant"><span
style='mso-bookmark:citations'><span lang=EN>[80]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=for%20receptive%20and%20expressive%20language,The%20standard%20of"><span
style='mso-bookmark:citations'><span lang=EN>[91]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=match%20at%20L855%20GPC3%2C%20GPC4,Wilms%20tumor%2C%20hepatoblastoma%2C%20neuroblastoma%2C%20gonadoblastoma"><span
style='mso-bookmark:citations'><span lang=EN>[115]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=NF2%20Schwannoma%2C%20meningioma%2C%20astrocytoma%2C%20ependymoma,Malignant%20peripheral%20nerve"><span
style='mso-bookmark:citations'><span lang=EN>[116]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=skin%20examination%20is%20important%20to,responsible%20for%20repairing%20a%20specific"><span
style='mso-bookmark:citations'><span lang=EN>[117]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=type%201%20%28predisposed%20to%20low,damage%20known%20as%20mismatch%20repair"><span
style='mso-bookmark:citations'><span lang=EN>[118]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=NF1%20Low,Malignant%20peripheral%20nerve%20sheath%20tumor"><span
style='mso-bookmark:citations'><span lang=EN>[119]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Schwannomatosis%20SMARCB1%20,LZTR1%20Schwannoma%2C%20meningioma%20SMARCB1%3A%20malignant"><span
style='mso-bookmark:citations'><span lang=EN>[120]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=Gorlin%20PTCH1%2C%20SUFU%20Medulloblastoma%20,symptomatic%20SUFU%3A%20Consider%20screening%20if"><span
style='mso-bookmark:citations'><span lang=EN>[121]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=medulloblastoma%2C%20hemangioblastoma%20Leukemia%2C%20gastrointestinal%20tumors%2C,others"><span
style='mso-bookmark:citations'><span lang=EN>[123]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_000000006788622f9a6ba13b97499b71#:~:text=match%20at%20L871%20medulloblastoma%2C%20hemangioblastoma,Leukemia%2C%20gastrointestinal%20tumors%2C%20others"><span
style='mso-bookmark:citations'><span lang=EN>[124]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> pedsinreview.2020004499.pdf</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_000000006788622f9a6ba13b97499b71"><span style='mso-bookmark:
citations'><span lang=EN>file://file_000000006788622f9a6ba13b97499b71</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=predisposition%20syndromes%2C%20including%20neurofibromatosis%20type,grade%20gliomas"><span
style='mso-bookmark:citations'><span lang=EN>[21]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%1750.4%E2%80%9354%20Gy%20with%20a%20cone,to%2054%20and%2060%20Gy"><span
style='mso-bookmark:citations'><span lang=EN>[24]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=MS,Subsequent"><span
style='mso-bookmark:citations'><span lang=EN>[34]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=multidisciplinary%20team%20with%20experience%20managing,will%20address%20additional%20tumor%20types"><span
style='mso-bookmark:citations'><span lang=EN>[35]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=match%20at%20L4821%20exhibited%20a,only%20one%20hospitalization%20for%20neutropenic"><span
style='mso-bookmark:citations'><span lang=EN>[47]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%97%8A%20Associated%20with%20colon%20cancer%2C,hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2"><span
style='mso-bookmark:citations'><span lang=EN>[59]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%28Gorlin%20syndrome%29%20SHH,activated%20medulloblastomas"><span
style='mso-bookmark:citations'><span lang=EN>[60]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%80%A2%20Most%20common%20in%20children,activated%20medulloblastomas"><span
style='mso-bookmark:citations'><span lang=EN>[61]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=disease%2C%20which%20has%20limited%20treatment,IMAGE%20FOR%20PAGE%3A%2081"><span
style='mso-bookmark:citations'><span lang=EN>[63]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=ped_cns%20NCCN%20Guidlines,2025"><span
style='mso-bookmark:citations'><span lang=EN>[64]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=NCCN%20Guidelines%20Version%203,For%20medulloblastomas%2C%20the"><span
style='mso-bookmark:citations'><span lang=EN>[65]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%80%A2%20Treatment%20for%20medulloblastoma%20includes,for%20histologic%20and%20molecular%20classification"><span
style='mso-bookmark:citations'><span lang=EN>[66]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=collectively%20referred%20to%20as%20%E2%80%9CNon,VP"><span
style='mso-bookmark:citations'><span lang=EN>[67]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%17CSI%2023,8%20Gy"><span
style='mso-bookmark:citations'><span lang=EN>[68]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%E2%80%A2%20High%20risk%20and%20very,8%20Gy"><span
style='mso-bookmark:citations'><span lang=EN>[69]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=WNT%2Fnon,age%20per%20the%20treating%20physician%E2%80%99s"><span
style='mso-bookmark:citations'><span lang=EN>[70]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=intermediate%20risk%20for%20medulloblastoma,years%2C%20then%20as%20clinically%20indicated"><span
style='mso-bookmark:citations'><span lang=EN>[74]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=%17Gorlin%20syndrome%20,Germline%20PTCH1%20and%20SUFU%20mutations"><span
style='mso-bookmark:citations'><span lang=EN>[76]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2%3B,CREBBP%2C%20and%20EP300%20can%20also"><span
style='mso-bookmark:citations'><span lang=EN>[77]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2%3B,CREBBP%2C%20and%20EP300%20can%20also"><span
style='mso-bookmark:citations'><span lang=EN>[78]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=match%20at%20L2216%20%E2%97%8A%20Associated,hMSH2%2C%20hMSH6%2C%20hMLH1%2C%20and%20hPMS2"><span
style='mso-bookmark:citations'><span lang=EN>[122]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> </span></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1#:~:text=therapies%20in%20patients%20whose%20tumors,artificial%20intelligence%20model%20or%20tool"><span
style='mso-bookmark:citations'><span lang=EN>[126]</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'><span
lang=EN> ped_cns NCCN Guidlines.pdf</span></span></p>

<p class=MsoBodyText><span style='mso-bookmark:citations'></span><a
href="file:///file_00000000dd40622fb25fa17d06391af1"><span style='mso-bookmark:
citations'><span lang=EN>file://file_00000000dd40622fb25fa17d06391af1</span></span><span
style='mso-bookmark:citations'></span></a><span style='mso-bookmark:citations'></span></p>

</div>

</body>

</html>
